Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects

6-2018

Effect of High Antioxidant Cacao Consumption on
Behaviors in Children with Autism Spectrum
Disorder
Amy Sadek

Follow this and additional works at: http://scholarsrepository.llu.edu/etd
Part of the Rehabilitation and Therapy Commons
Recommended Citation
Sadek, Amy, "Effect of High Antioxidant Cacao Consumption on Behaviors in Children with Autism Spectrum Disorder" (2018).
Loma Linda University Electronic Theses, Dissertations & Projects. 522.
http://scholarsrepository.llu.edu/etd/522

This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative
Works. It has been accepted for inclusion in Loma Linda University Electronic Theses, Dissertations & Projects by an authorized administrator of
TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. For more information, please contact
scholarsrepository@llu.edu.

LOMA LINDA UNIVERSITY
School of Allied Health Professions
in conjunction with the
Faculty of Graduate Studies

____________________

Effect of High Antioxidant Cacao Consumption on Behaviors in Children with
Autism Spectrum Disorder
by

Amy Sadek

____________________

A Dissertation submitted in partial satisfaction of
the requirements for the degree
Doctor of Philosophy in Rehabilitation Science

____________________

June 2018

© 2018
Amy Sadek
All Rights Reserved

Each person whose signature appears below certifies that this dissertation in his/her opinion
is adequate, in scope and quality, as a dissertation for the degree Doctor of Philosophy in
Rehabilitation Science.

, Chairperson
Lee S. Berk, Professor of Allied Health Studies

Noha S. Daher, Professor of Epidemiology and Statistics

Karen Mainess, Assistant Professor of Communication Sciences and Disorders

Kiti Freier Randall, Medical Director of the Inland Empire Autism Assessment Center of
Excellence

iii

ACKNOWLEDGEMENTS

As I reflect on the journey of getting to this point in my doctoral program I am
appreciative beyond measure to the people it took to make this possible. First and
foremost, I thank God, for giving me the courage and wisdom to take on this somewhat
daunting task knowing that through faith in Him, I could accomplish even the most
challenging of obstacles.
Second, my chair and mentor, Dr. Berk, thank you for taking me under your wing
and showing me the fun in the journey of asking questions and that asking questions
often leads to more questions. Your peaceful leadership led me to discover my own
potential which I would not have known before this journey. Thank you for your
encouragement and reminders of the joys of being a life-long learner.
Third, thank you Dr. Daher for being such an encouragement with what is
seemingly the more, if not the most, challenging topic in the program, statistics. You are
an exemplary scholar, teacher, and friend. You took time to guide me and lead me to
success and I am excited to continue using the knowledge you have shared with me not
only in statistics but in academia, scholarly work, and life.
Fourth, thank you Dr. Mainess for always giving me sound advice and feedback
and being a student advocate. You have been such a source of positivity to work with and
I was truly inspired by your work in your field and your contribution to Autism research.
Fifth, thank you Dr. Kiti Freier Randall for your clinical expertise and contributions to
the project and to the Autism community. Lastly, I thank my parents who are my rocks
and biggest cheerleaders. Thank you for encouraging me when I felt discouraged to
continue and for reminding me of the value of hard work not only by your individual

iv

examples but by your hard work in taking care of our family. I would also like to thank
my sister Shelly who has been an inspiration to me since I was a little girl. I watched you
go through your dissertation five years ago and thought there is no way I would or could
ever do that and somehow here I am. It is an honor to walk in your footsteps and thank
you for always being a listening ear, shoulder to cry on, and source of strength and
encouragement.

v

CONTENT

Approval Page ................................................................................................................. ...iii
Acknowledgements ............................................................................................................ iv
List of Tables ..................................................................................................................... ix
List of Abbreviations ...........................................................................................................x
Abstract .............................................................................................................................. xi

Chapter
1. Introduction and Review of the Literature ...............................................................1
Autism Spectrum Disorder ................................................................................1
Traditional Therapies .........................................................................................1
Behavioral Therapy......................................................................................2
Special Education and Autism .....................................................................3
Family Stress and Autism ............................................................................3
Pharmacological Interventions...........................................................................4
A Physiological Perspective: Oxidative Stress ..................................................5
Oxidative Stress and ASD .................................................................................6
Antioxidants and Nutrition ................................................................................8
Cacao as an Antioxidant ....................................................................................9
Neurocognitive Benefits of Cacao ...................................................................14
Antioxidants, Autism, and Behavior ................................................................15
Significance of the Present Study ....................................................................17
References ........................................................................................................19
2. Antioxidants and Autism: Teachers’ Perceptions of Behavioral Changes ............24
Abstract ............................................................................................................25
Introduction ......................................................................................................27
Methods............................................................................................................31
Study Design ..............................................................................................31
Participants .................................................................................................31
Procedures and Interventions .....................................................................32
Measures ....................................................................................................33
Statistical Analyses ....................................................................................34

vi

Results ..............................................................................................................34
Discussion ........................................................................................................35
Conclusion .......................................................................................................37
Ethics Statement...............................................................................................38
Acknowledgements ..........................................................................................38
References ........................................................................................................42
3. A Pilot Study: Parent Perceptions of Behavior Change in their ASD Child
Following High Antioxidant Cacao Consumption ................................................48
Abstract ............................................................................................................49
Introduction ......................................................................................................50
Autism Spectrum Disorder ........................................................................50
Conventional Therapies .............................................................................50
Oxidative Stress and ASD .........................................................................52
Methods............................................................................................................54
Study Design ..............................................................................................54
Participants .................................................................................................55
Procedures and Interventions .....................................................................55
Measures ....................................................................................................56
Statistical Analyses ....................................................................................57
Results ..............................................................................................................58
Discussion ........................................................................................................59
Conclusion .......................................................................................................63
Ethics Statement...............................................................................................64
Acknowledgements ..........................................................................................64
References ........................................................................................................69
4. Discussion… ..........................................................................................................75
Conclusion .......................................................................................................79
References ........................................................................................................80

vii

Appendices
A. Parent Informed Consent Form...........................................................................82
B. Special Education Teacher Informed Consent ....................................................86
C. Authorization for Use of Protected Health Information .....................................89
D. California Experimental Subject’s Bill of Rights ...............................................92
E. Participant’s Demographic Form ........................................................................93
F. Aberrant Behavior Checklist 2nd Edition Questionnaire .....................................97
G. Autism Spectrum Rating Scale .........................................................................100
H. Parental Stress Index Short Form .....................................................................102
I. Youth and Adolescent Food Frequency Questionnaire ....................................104
J. Data Collection Form ........................................................................................105
K. Letter of Recruitment for Flyer Distribution ....................................................106
L. Allergic Reaction Fact Sheet ............................................................................107
M. Flyer for Recruiting Participant ........................................................................108

viii

TABLES

Tables

Page

Chapter 2
1. Participant characteristics (N = 12)........................................................................39
2. Child’s medical history and type of therapy (N=12) .............................................40
3. Median (min, max) Scores for ABC-2 and ASRS over time .................................41
Chapter 3
1. Participant characteristics (N = 16)........................................................................65
2. Child’s medical history and type of therapy (N=16) .............................................67
3. Median (min, max) Scores for ABC-2 and ASRS over time .................................68

ix

ABBREVIATIONS

ASD

Autism Spectrum Disorder

CDC

Center for Disease Control and Prevention

WHO

World Health Organization

ABA

Applied Behavioral Analysis

EIBI

Early Intensive Behavioral Intervention

SSRIs

Selective Serotonin Reuptake Inhibitor

FDA

Food & Drug Administration

ROS

Reactive Oxygen Species

EEG

Electroencephalogram

NAC

N-Acetylcysteine

CAM

Complementary and alternative medicine

ASRS

Autism Spectrum Rating Scale

TE

Trolox equivalent

ABC

Aberrant Behavior Checklist

CF

Cocoa flavanols

FRC

Flavanoid rich cocoa

x

ABSTRACT OF THE DISSERTATION

Effect of High Antioxidant Cacao Consumption on Behaviors in Children with
Autism Spectrum Disorder
by
Amy Sadek
Doctor of Philosophy, Graduate Program in Rehabilitation Science
Loma Linda University, June 2018
Dr. Lee S. Berk, Chairperson

BACKGROUND- Children with Autism Spectrum Disorder (ASD) demonstrate
a physiological imbalance between free radicals, resulting from oxidative stress, and
antioxidants. Oxidative stress is linked to the pathogenesis of this neurocognitive
disorder. The objectives of this pilot feasibility study: 1) to examine the effect of
consumption of high concentration antioxidant cacao on behavior of children as
perceived by the child’s teacher and 2) as perceived by the child’s parent.
METHODS- This clinical trial was a prospective experimental study. Participants
consumed 8 squares (or 16 grams) per day of the dark chocolate which had a
concentration of 70% cacao and 30% organic cane sugar (total antioxidant concentration
was 8,320 µmoles / 100 grams. The two main behavioral measures were the Aberrant
Behavior Checklist- 2nd Edition (ABC-2) and the Autism Spectrum Rating Scale (ASRS)
which were completed by the child’s teacher at baseline and end of week four; and by the
child’s parent at baseline, week two, and week four.
RESULTS- Twelve teachers and children with ASD (9 males, 3 females, mean
age of 10.9 ±3.9 years) participated in this study. Teachers noted significant
improvements on the Autism Spectrum Rating Scales of Social/Communication (p=0.03,
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η2=0.79), Unusual Behaviors (p=0.02, η2=0.70), and Self-Regulation (p=0.04, η2=0.59).
No significant changes were noted on any of the Aberrant Behavior Checklist-2 subscales
(p>.05). For the second study, sixteen parents and children with ASD participated in the
study (12 males, 4 females, aged 4 to 17 years). Parent reports showed significant
improvements on the ABC-2 subscales of Irritability (p= .03, η2 = 0.25), Social
Withdrawal (p=.01, η2 = 0.29), Stereotypic Behavior (p=.05, η2 = 0.13),
Hyperactivity/Noncompliance (p=.04, η2 = 0.20), and Inappropriate Speech (p=.05, η2 =
0.16). Significant improvements were noted on the ASRS scales of
Social/Communication (p=.04, η2 = 0.25), Unusual Behaviors (p=.003, η2 = 0.20), SelfRegulation (p=0.02, η2=0.32), and Total Scores (p<.001, η2=0.54).
CONCLUSION- Results from this study support the therapeutic benefit of
antioxidants in improving social communication, unusual behaviors, and self-regulation
behaviors of children with ASD. Further robust randomized controlled trials are
necessary to elaborate the validity of these finding.
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CHAPTER 1
INTRODUCTION AND REVIEW OF THE LITERATURE
Autism Spectrum Disorder
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that is
characterized by deficits in social and communication skills, functional impairments
across multiple settings, repetitive and restrictive behaviors, as well as hyper or hypo
responsiveness to sensory stimuli in the environment 1. According to the Center for
Disease Control and Prevention (CDC), currently in the United States (U.S.), 1 in 68
children are identified as having ASD with it being four and a half times more prevalent
in males than females 2. According to the World Health Organization (2017), worldwide,
one in 160 children have ASD. Although the etiology of ASD remains elusive, there are
genetic, environmental, immunological, and oxidative stress influences that are related to
the pathogenesis of the disorder 3,4.
Additionally, perinatal and neonatal risk factors such as, “abnormal fetal
presentation, umbilical-cord complications, fetal distress, birth injury or trauma, multiple
birth, maternal hemorrhage, summer birth, low birth weight, small for gestational age,”
among others have been identified as part of the association with ASD 5. The
heterogeneity of ASD lends itself to the need for a variety of interventions, both
traditional and non-traditional, as no one technique works across the spectrum.

Traditional Therapies
Behavioral therapists, speech and language pathologists, and occupational
therapists are common interventionists that work with children on the spectrum.
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Behavioral therapists work with ASD children on maladaptive behaviors, language skills,
daily living skills, and social functioning. This type of applied behavioral analysis
(ABA), uses a Skinner approach with rote discrete trials in a one on one setting and is
typically recommended at 40 hours per week for years on end 6,7. Speech and Language
Pathologists also work with children with ASD to target social communication skills,
request making, speech production, alternative communication strategies, and reciprocal
interaction skills (American Speech-Language-Hearing Association, 2006). Occupational
therapists target sensory processing skills through regulatory strategies across
environments, activities of daily living related to school and home performance, and
motor skills required for activities in their educational setting 9. In general, behavioral
therapists work on maladaptive behaviors, speech therapists work on communication
skills, and occupational therapists work on self-regulation skills as they relate to hypo or
hyper responses to environmental stimuli.

Behavioral Therapy
Early intensive behavioral intervention (EIBI) is a common behavioral approach
used in children with ASD. It is typically recommended for 40 hours per week for a
minimum of two years 6. A meta-analysis on the effectiveness of this approach revealed
that children in experimental groups had better IQs and adaptive behavior outcomes
compared to control groups who received a less intense approach 6. Although ABA
techniques are common and popular in addressing aberrant ASD behaviors, the evidence
remains mixed as studies did not have a uniform or equally replicable methodology to
show consistency of results.
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Special Education and Autism
Children with ASD often receive the aforementioned services through their
special education program. Furthermore, it should be noted that both special education
and general education teachers educate students with ASD 10. Evidence based practices
are limited in nature for the ASD population due to the heterogeneous profiles of the
disorder and often times practitioners implement a variety of strategies that have not been
studied in combination 11. Additional barriers for educators and practitioners include the
child’s behaviors which make conducting standardized assessments challenging to
accurately develop goals and treatment plans in the school environment 12. Overall, there
is limited evidence on teachers’ perceptions of ASD behaviors in the classroom setting
yet these behaviors bring challenges when it comes to educational engagement from the
ASD student.

Family Stress and Autism
As with any disease or disorder that has a life-long course, the stress of being a
parent or caregiver of a child with ASD naturally comes with the territory. The child’s
behaviors, including but not limited to, anxiety, tantrums, self-injury, or outbursts may
cause the family unit additional stress making daily life tasks more burdensome 13.
Parents have reported feelings of anger, doubt, and disbelief at the time of their childs’
diagnosis 13. Additionally, maladaptive behaviors had a negative effect on parent sleep
and many parents reported missing work or quitting work as a result 13. Parental stress
should also be considered when weighing the consequence of aberrant behaviors of
children with ASD. These ripple effects on the family unit show the colossal impact that
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ASD behaviors can have and as a result require our attention to address and alleviate as
much as possible.

Pharmacological Interventions
In terms of pharmacological interventions, approximately one third of the ASD
population take Selective Serotonin Reuptake Inhibitor (SSRIs) drugs because their
behaviors are similar to other serotonin related disorders 14. There are only two Food &
Drug Administration (FDA) approved drugs for ASD, Risperidone and Abilify 14.
Risperidone is a second-generation antipsychotic that has helped children with ASD
reduce their number of tantrums, aggressive behaviors, and self-injurious behaviors 14.
Abilify is a psychotropic drug designed to treat mood irritability in children with ASD
14,15

. However, as with any drug, there are associated adverse effects including increased

appetite, weight gain, dizziness, drooling, drowsiness, fatigue, vomiting, nasopharyngitis,
fever, insomnia, and upper respiratory infections 14-16. Non-pharmacological lifestyle
oriented interventions may compliment traditional therapies in targeting behavior, mood,
and performance issues associated with ASD without side effects of medication 17.
When the aforementioned therapies and pharmaceutical agents are considered the
cost of ASD becomes colossal. A recent study reported that the cost of ASD, across one’s
lifetime, in the U.S. is $1.4 million, and $2.4 million, respectively, if they also have an
intellectual disability 18. However, as with any disability or disorder the cost is indefinite
as there are also psychological and stress costs that cannot be quantified for the
individuals or families caring for them. Lifestyle oriented approaches may, then, be
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necessary not only to potentially offset costs but to improve quality of life in a long term
sustainable fashion.

A Physiological Perspective: Oxidative Stress
Oxidative stress leads to an excess accumulation of free radicals in the body and
has been linked to a variety of diseases including cancer, cardiovascular disease,
neurological diseases, pulmonary disease, rheumatoid arthritis, nephropathy, epilepsy,
allergies, inflammation, as well as ocular disease 19,20. Although oxygen is a life
sustaining necessity, the influence of oxidative stress causes oxygen to have harmful
effects on the human body 21. Oxidative stress can be simply defined as disequilibrium
between reactive oxygen species (ROS), also known as free radicals, and antioxidants
(Hossain, ASM Matiur, & Alam, 2014). Essentially these ROS donate oxygen to
otherwise stable molecules and thus disrupt their function by oxidizing them 21. This
imbalance can damage any one of our organ systems and can alter DNA structure and
compromise the integrity of cellular membranes (Hossain, ASM Matiur, & Alam, 2014).
Furthermore, the human brain occupies approximately two percent of our body weight
yet utilizes a quarter of our energy required at rest 23. This is important in the pediatric
population because young children are highly susceptible to oxidative stress during early
development because their protective barriers against oxidative damage are not fully
formed.
Though the exact mechanisms on the pathogenesis of neurocognitive disorders
remains under scientific investigation, there is an identifiable link between the excess of
free radicals and neuronal damage. Recently, scientists have also studied oxidative stress
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as part of the pathophysiology of ASD, as well its potential link to other neuropsychiatric
disorders such as schizophrenia, major depressive disorder, anxiety, panic disorder,
Alzheimer’s disease, Parkinson’s disease, and obsessive compulsive disorders 3,23. Due to
the brain’s high energy requirements, specifically neurons, which require the most energy
of any brain cell are limited in their antioxidant defense making them the first cells to be
negatively impacted 23. It is clear that the deleterious effects of oxidative stress can
significantly impact brain and cellular function of many organ systems.

Oxidative Stress and ASD
Although the etiology of ASD is multifactorial, research suggests that there are
some neurophysiological differences between individuals with and without ASD 24,25. For
example, irregularities in neuronal connections have been associated with “cognitive,
social, and sensory behavioral symptoms,” (Dinstein et al., 2011, p. 1218). Furthermore,
due to the limited number of studies that have examined where the brain abnormalities
are and the various regions studied it is difficult to determine if the differences are
localized in the brain or more systemic 25. Of particular relevance to the current study is
research on oxidative stress and ASD symptomology. Damodaran, Arumugam 3 reported
a significant increase in oxidative stress markers in children with ASD compared to
matched controls and the level of antioxidants excreted in urine samples were
significantly lower in children with ASD compared to matched controls. Furthermore, the
severity of autistic behaviors was positively correlated with oxidative stress markers,
whereas antioxidant levels were negatively correlated with autistic behaviors 3,26.
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Additional evidence from Ming et al. (2005), who measured urinary excretion of
8-iisoprostane and 8-hydroxy-2-deoxyguanosine in children with ASD and matched
controls and found that children with ASD had increased levels of lipid peroxidation,
indicating further mechanism for oxidative stress patterns. In addition, elevated blood
samples of glutathione, glutathione peroxidase, methionine, oxidized glutathione, and
cysteine have also been found in children with ASD 26. Since free radicals, when in
excess, can be so deleterious to mind-body health it is imperative that antioxidants be
incorporated as supportive therapies for neutralizing oxidative stress.
Ming and colleagues (2005) suggests that children with ASD tend to have greater
markers of oxidative stress compared to age matched controls or their non-Autistic
siblings. Oxidative stress can be due to mitochondrial impairment, environmental factors,
metabolic issues, and genetic predisposition 20,25. In turn, oxidative stress can lead to a
cascade of events such as inflammation, damage to cell membranes, autoimmunity,
methylation damage, cell death, and neurological impairments 26. Oxidative stress can be
identified through markers of antioxidant enzymes, lipid peroxidation, and protein
oxidation, all of which are higher in children with autism compared to their matched
controls 3,20,25. It is evident that this imbalance between free radicals and antioxidants
creates a plethora of detrimental physiological outcomes and are contributory to the
pathogenesis of ASD. In summary, these studies provide growing evidence regarding the
physiological differences in children with ASD that show an imbalance in the oxidation
of antioxidants and thus an excess of free radicals.
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Antioxidants and Nutrition
The human body offers natural mechanisms to counter the damaging effects of
free radicals that lead to oxidative stress by producing antioxidants. Antioxidants can be
produced endogenously by the body or can be ingested through dietary nutrients.
Endogenous antioxidants include glutathione, ceruloplasmin, transferrin, catalase,
superoxide dismutase, and glutathione peroxidase 4. Examples of dietary antioxidants
include but are not limited to Vitamin E, Vitamin C, Beta-carotene, Lycopene, Selenium,
Omega-3 fatty acids, Omega-6 fatty acids, and Flavonoids 19. Polyphenols are also
considered a larger category of antioxidants which are phytochemicals that are found in
large quantities in fruits, vegetables, and other natural nutrients 27.
Many antioxidant rich foods and vitamins have been used in the treatment of
disease 28. For example, vitamin C and vitamin E are both rich in antioxidants and have
been used for cardiovascular disease and cancer 28. Carotenoids have also been used in
diseases that are neurodegenerative, inflammatory, or cardiovascular in nature 28.
Additionally, polyphenols such as flavanols and flavonoids have free radical scavenger
properties making them beneficial in combatting chronic diseases 29. The cocoa bean has
higher antioxidant properties than teas and wines as they have higher concentrations of
flavonoids making it a highly valuable nutrient in health promotion 29. Overall,
antioxidants can be considered beneficial for protection against chronic diseases and are
often found in functional super foods such as berries, cacao, and green tea 30.
To date, there is not an antioxidant specific validated and reliable nutrition survey
that applies to children or adults. However, the Youth Adolescent Food Frequency
Questionnaire is a validated measure developed out of Harvard 31. The questionnaire
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comprises nine main content areas of foods frequently consumed; eight questions on
demographics, 20 questions on consumption of various beverages, 16 dairy food items,
30 questions on main dishes, six questions on types of sandwiches, eight questions on
other food consumption, 17 questions on breads and grains, 41 questions on fruits and
vegetable consumption, and 31 questions on snacks and desserts. The questions are
ranked depending on how frequent the food items are consumed; from never to less than
once per month, one to three times a week, once per week, two to four times per week,
more than four times per week, and once per day. The category related to fruits and
vegetables is the closest measure of children’s intake of foods that would be rich with
antioxidants and thus this questionnaire was employed in this study.

Cacao as an Antioxidant
In the typical U.S. diet, chocolate is the leading source of antioxidants followed
by fruits and vegetables 32. Cocoa is potent in antioxidants such as flavanols which play a
role in neuroregulatory mechanisms such as anti-inflammation and vasodilatory
properties 33. Polyphenols, such as those found in cacao, are known to have the ability to
remove free radicals from the body and can offer protective properties in disease such as
arteriosclerosis, heart disease, and alcoholic fatty liver 28. In addition, flavanoids have
potent antioxidant content and are derived from foods such as cacao, green tea, grapes,
apples, ginkgo biloba, berries, among other foods 19. Antioxidants found in cacao include
several subclasses such as polyphenols, flavonoids, and flavanols. Within flavanols, we
find catechin, epicatechin, epigallocatechin, and epigallocatechin gallate all of which are
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found naturally in cacao 29,34. Consequently, it is evident that dietary antioxidants can be
easily consumed and beneficial for overall health.
Thus, although oxidative stress is associated with a variety of neurological
disorders, promising research from ASD and Down Syndrome participants suggests that
the counteracting effects of antioxidants may minimize free radical damage, thereby
reducing symptoms of irritability, hyperactivity and improving the physiological balance
between free radicals and antioxidants 35,36. For example, in a recent study on children
and adolescents with Down Syndrome, researchers found support for antioxidant
supplementation through use of vitamin E, vitamin C, E-TABS, and Energil C in
reducing oxidative stress biomarkers with lasting effects even after the six-month
intervention 36. Nutrition plays an integral role on health via antioxidants. Antioxidants
have great physiological and neurological benefit given their defense against toxic free
radicals when normal mechanisms experience disequilibrium.
Oxidative stress biomarkers are particularly noteworthy as they have the potential
to be modulated by means of non-pharmacological interventions, such as nutritional
interventions. Cacao is a food rich in flavonoids and their sub group flavanols. For the
purposes of this introduction, cacao and cocoa were used interchangeably. Both are
associated with improved cognitive processing, alertness, and processing speed 37.
Further benefits of cocoa include increased cerebral blood flow, improved cardiovascular
activity, improved insulin resistance, improved blood pressure, and improved endothelial
function 37. Antioxidants’ benefits include improvement of cellular structure, neutralizing
free radicals, neuroprotective, anti-inflammatory, accumulation in the hippocampus and
cortex, and improvement of vascular endothelial function 27,32,34.
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More specifically, cacao is a natural and potent antioxidant with benefits linked to
improvements in blood pressure, lipid peroxidation, cognitive response time, gamma
frequency, and cerebral blood flow 27,32,38-40. Additionally, flavanoids’ ability to cross the
blood brain barrier demonstrates their neuroprotective mechanisms as well as their role in
cognitive functions such as learning and memory 34,41. The aforementioned studies
summarize the inherent value in cacao as a natural superfood the mind and the body.
Scholey, French, Morris, Kennedy, Milne, Haskell 42 studied healthy adults and
randomly assigned participants to one of three groups with one group consuming a
beverage containing 520 milligrams (mg) of cocoa flavanols (CF), a second group
consuming a beverage containing 994 mg of CF, and a matched control. Results showed
that the groups who consumed 520 mg of CF and 994 mg of CF significantly improved
scores on a cognitive battery test 42. In addition, the 994 mg of CF beverage resulted in
significant improvement in rapid visual information processing 42. Field, Williams, Butler
43

also studied healthy adult subjects who consumed chocolate containing 720 mg of CF

and a matched quantity of white chocolate, which served as the control group as white
chocolate lacks cacao. Researchers found that the flavanol group improved in visual
contrast sensitivity, reduced the time required to detect motion direction, and improved
spatial memory 43. Both of these studies noted that while the mechanisms underlying the
effects are unknown they may be related to effects of CF on endothelial function and
blood flow which allows improved transfer and delivery of oxygen and nutrients
systemically.
Mastroiacovo, Kwik-Uribe, Grassi, Necozione, Raffaele, Pistacchio, Righetti,
Bocale, Lechiara, Marini, Ferri, Desideri 39 examined elderly subjects who showed
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clinical evidence of cognitive deficits and had them consume a drink everyday for eight
weeks with various concentrations of flavanols. One group consumed high flavanols 993
mg, the intermediate group consumed 520 mg of flavaonol, and the low flavanol group
consumed 48 mg 39. Results revealed an overall improvement in response time and verbal
fluency scores in all three groups with greatest improvement being in the highest
concentration group 39. They also found physiological benefits with improvements in
insulin resistance, blood pressure, and lipid peroxidation in the high flavanol group and in
the intermediate flavanol group 39. These results are noteworthy as lipid peroxidation is a
mechanism of oxidative stress that occurs when free radicals damage the lipid cellular
membrane and thus destroy the integrity of the cell and its functions.
Davison, Berry, Misan, Coates, Buckley, Howe 44 aimed to determine a minimum
dose effect of flavanol rich cocoa products relative to lowering blood pressure in men and
women with mild untreated hypertension. Participants consumed a daily cocoa beverage
containing 33, 372, 712 or 1052 mg of cocoa flavanols per day 44. Significant reductions
were noted only in the 1052 mg/day group, no reduction was seen at any other dose in
this particular study 44. In another study, Grassi, Desideri, Necozione, di Giosia,
Barnabei, Allegaert, Bernaert, Ferri 45 examined cocoa flavonoids on cardiovascular
functions in healthy adults. Total flavanoid concentration ranged from zero mg for the
control group to 80, 200, 500 and 800mg per day on each week. Compared with controls,
all cocoa-active treatments significantly and dose-dependently increased flow mediated
vasodilation 45. Results also showed improvements in arterial stiffness and blood pressure
during each week of treatment 45. A previously conducted cross sectional study on older
adults demonstrated a dose response relationship with a flavonoid rich beverage
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consumption at 10 grams per day for optimal cognitive benefit 46. However, the
antioxidant concentration and percentage of cacao were not noted or controlled for in this
study which limits the generalizability of the dose dependent outcomes. Further research
is still needed to reproduce these effects in similar samples and eventually show a
consistent dose response.
A meta-analysis was conducted to evaluate the effect of flavanoid rich cocoa
(FRC) on cardiovascular risk factors and to assess a dose-response relationship and the
studies reviewed included samples of healthy, diabetic, overweight, and heart disease
subjects 47. Results showed that in response to FRC consumption, systolic blood pressure
decreased, insulin resistance decreased, Low Density Lipoprotein cholesterol decreased,
flow mediated vasodilation increased, and High Density Lipoprotein cholesterol
increased 47. A dose-response relationship was found between FRC and flow mediated
vasodilation with a maximum effect observed at a flavonoid dose of 500 mg/day 47. The
above literature points to the benefits that cocoa has, particularly, the flavanols and
flavonoids which are nutritional antioxidants, on a variety of physiological mechanisms.
Richelle, Tavazzi, Enslen, Offord 48 conducted a study on adult males, both
smokers and non-smokers, analyzing the peak concentration of epicatechins from blood
samples following consumption of dark chocolate. Findings from this study suggest that
epicatechins, a subgroup of polyphenol antioxidants, peak in the blood at approximately
two hours after 40 grams were consumed and at approximately three hours after 80 grams
were consumed 48. More recent research echoes these findings that epicatechins,
antioxidants naturally found in cacao, peak in the blood two to three hours following
consumption and resume a baseline level six to eight hours later 49,50. In a review article
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by Vauzour 40, the neurological benefits of polyphenols, including those found in cacao
are identified as promoting neurogenesis and neurocognitive functions. For example,
polyphenols have been noted to cross the blood brain barrier in both animal and human
studies suggesting their neuroprotective features not only to support the antioxidant
defense against oxidative stress but also in modulating inflammation in the brain 40. Both,
Richelle, Tavazzi, Enslen, Offord 48 and Vauzour 40, may support the benefit of
maintaining a certain level of concentration in the bloodstream for physiological and
neurocognitive benefits. Future studies need to examine the amount of specific dietary
antioxidants’ and their absorption for dosing recommendations and therapeutic purposes
in human subjects.

Neurocognitive Benefits of Cacao
In addition to physiological health benefits noted above, there are also
neurocognitive benefits to cacao consumption. Berk et al. (2016) found that when healthy
adults consumed 70% cacao gamma wave frequency was elicited as measured by
electroencephalogram (EEG) of the brain. Gamma wave frequency (γBA 31–40 Hz) is
the highest brain frequency associated with long term recall, neural synchronization,
learning, and heightened meditation (Berk et al., 2016). In a follow up study, they found
similar results in healthy adults who consumed 70% cacao with nine cerebral cortical
EEG leads to measure brain activity which again produced gamma wave frequencies
(γBA 31–40 Hz) (Berk et al., 2017).
Furthermore, gamma frequency has been studied in both animal and human
models and findings support that this high-level frequency is associated with short term
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memory, long term memory, enhanced neuronal communication and synchronization 51.
The rapidity of gamma wave frequencies results in firing of the tight and rhythmic
oscillations of the neuron thus allowing for faster interneural communication 51. This
research suggests both the neuroprotective and neuromodulatory benefits of high
antioxidant cacao on brain health. Gamma frequency also plays a role in working
memory, memory retrieval, and attention skills 52. Future studies will need to identify if
these changes in brain wave frequency carryover to attention and task performance on
participants with neurocognitive disorders. The aforementioned studies point to the
critical and valuable role that gamma wave frequencies play in higher cognitive
processing skills which would be advantageous for the ASD population.
The above literature repeatedly points to both the health and physiological
benefits of cacao on adults. To date, to the author’s knowledge, only one study has
looked at potential health benefits of cacao on children. Children with idiopathic
constipation between the ages of three and six consumed four grams of cocoa husk per
day and children between the ages of seven and 10 consumed eight grams per day 53. The
children who received cocoa husk supplements tended to increase the number of bowel
movements compared to the placebo group 53. Although this study was not related to
ASD, nor to the concentration of cacao or flavanols, it shows limited evidence on health
benefits of cacao for children.

Antioxidants, Autism, and Behavior
In the ASD population, five studies have been conducted looking at an
antioxidant intervention relative to behavior change. According to the first identified
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study of its kind, researchers examined use of high antioxidant vitamin C providing eight
grams per 70 kilograms per day for 30 weeks and found a reduction in symptom severity
54

. This study examined antioxidants’ potential benefit to children with ASD. In 2013,

Ghanizadeh and Moghimi-Sarani, studied children between the ages of three and a half
and 16 and the children were randomly assigned to one of two groups. One group
received N-Acetylcysteine (NAC) (1200 mg/day) plus risperidone and the other received
placebo plus risperidone 55. N-Acetylcysteine is an antioxidant pro-drug and a precursor
to arguably the most important antioxidant, glutathione. Results showed a significant
improvement in irritability in the NAC group on the Aberrant Behavior Checklist 55.
More recently, researchers examined children between four and 12 years of age
where one group received risperidone plus NAC and the control group received
risperidone plus a placebo 56. The dose of NAC ranged from 600 to 900 mg/day 56.
Results showed a significant improvement in both irritability and
hyperactivity/noncompliance subscales on the Aberrant Behavior Checklist 56. The most
common noted adverse effects in the NAC plus risperidone group were constipation,
increased appetite, fatigue, nervousness, and daytime drowsiness 55,56.
Lastly, a recent pilot study assessed NAC in children with ASD between ages
three and 12 35. Subjects were randomized to the NAC or control group and were initiated
at 900mg/daily for four weeks, then 900 mg twice daily for four weeks, and 900 mg three
times daily for four weeks 35. Follow-up data revealed that the NAC group showed
significant improvements on the Aberrant Behavior Checklist irritability subscale
compared to the control group 35. Also, stereotypy behaviors improved on the repetitive
behavior scale and social cognition improved on one of the subtests on the social
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responsiveness scale 35. These studies are key in showing some of the reproducible
evidence of potential therapeutic effects and improved behavioral outcomes following
antioxidant interventions in children with ASD.

Significance of the Present Study
Traditional behavioral interventions for ASD, although valuable, are missing a
holistic approach as they typically do not target the physiological components to
neurocognitive deficits related to oxidative stress. The antioxidant and free radical
imbalance in ASD may require the combination of traditional therapies and nutritional
interventions to complement each other for optimal outcomes and quality of life for
children and families living with ASD. To date, to the author’s knowledge, previous
literature has not examined the potential association between antioxidant rich foods, such
as cacao, and ASD behaviors. However, based on the literature reviewed, oxidative stress
markers, such as free radicals, are elevated in children with ASD and thus can be reduced
by high antioxidant consumption, specifically cacao. Thus, the purpose of the study was
to provide information on the relationship between consuming high antioxidant cacao and
behavior in children with ASD. Specifically, this study aimed to examine the following
research questions:
1. What is the impact of consuming high antioxidant cacao on the severity of
Autistic behaviors?
2. What is the parents’ perspective on their child’s Autistic behaviors following
cacao consumption?
3.

What is the teachers’ perspective on their Autistic student’s behaviors following
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cacao consumption?
4.

What is the impact on parental stress following the cacao consumption
intervention?

18

References
1.

APA. Diagnostic and statistical manual of mental disorders:
DSM-5. Washington, D.C.: American Psychiatric Association; 2013.

2.

CDC. Autism Spectrum Disorder: Data & Statistics. 2016;
https://www.cdc.gov/ncbddd/autism/data.html.

3.

Damodaran LP, Arumugam G. Urinary oxidative stress markers in children with
autism. Redox Rep. 2011;16(5):216-222.

4.

Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology.
2006;13(3):171-181.

5.

Gardener H, Spiegelman D, Buka SL. Perinatal and neonatal risk factors for
autism: a comprehensive meta-analysis. Pediatrics. 2011;128(2):344-355.

6.

Peters-Scheffer N, Didden R, Korzilius H, Sturmey P. A meta-analytic study on
the effectiveness of comprehensive ABA-based early intervention programs for
children with autism spectrum disorders. Research in Autism Spectrum Disorders.
2011;5:1.

7.

Virues-Ortega J. Applied behavior analytic intervention for autism in early
childhood: meta-analysis, meta-regression and dose-response meta-analysis of
multiple outcomes. Clin Psychol Rev. 2010;30(4):387-399.

8.

Association AS-L-H. Principles for speech-language pathologists in diagnosis,
assessment, and treatment of autism spectrum disorders across the life span. 2006;
https://www.asha.org/policy/tr2006-00143/.

9.

Case-Smith J, Arbesman M. Evidence-based review of interventions for autism
used in or of relevance to occupational therapy. Am J Occup Ther.
2008;62(4):416-429.

10.

Robertson K, Chamberlain B, Kasari C. General education teachers' relationships
with included students with autism. J Autism Dev Disord. 2003;33(2):123-130.

11.

Dingfelder HE, Mandell DS. Bridging the research-to-practice gap in autism
intervention: an application of diffusion of innovation theory. J Autism Dev
Disord. 2011;41(5):597-609.

12.

Koegel L, Matos-Freden R, Lang R, Koegel R. Interventions for children with
autism spectrum disorders in inclusive school settings. Cognitive and Behavioral
practice. Cognitive and Behavioral Practice. 2012;19(3):401-412.

19

13.

Ooi KL, Ong YS, Jacob SA, Khan TM. A meta-synthesis on parenting a child
with autism. Neuropsychiatr Dis Treat. 2016;12:745-762.

14.

LeClerc S, Easley D. Pharmacological therapies for autism spectrum disorder: a
review. P T. 2015;40(6):389-397.

15.

Jobski K, Höfer J, Hoffmann F, Bachmann C. Use of psychotropic drugs in
patients with autism spectrum disorders: a systematic review. Acta Psychiatrica
Scandinavica. 2017;135(1):8-28.

16.

Lacivita E, Perrone R, Margari L, Leopoldo M. Targets for Drug Therapy for
Autism Spectrum Disorder: Challenges and Future Directions. J Med Chem.
2017;60(22):9114-9141.

17.

Weber W, Newmark S. Complementary and alternative medical therapies for
attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am.
2007;54(6):983-1006; xii.

18.

Buescher AV, Cidav Z, Knapp M, Mandell DS. Costs of autism spectrum
disorders in the United Kingdom and the United States. JAMA Pediatr.
2014;168(8):721-728.

19.

Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and
health. Int J Biomed Sci. 2008;4(2):89-96.

20.

Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC.
Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins
Leukot Essent Fatty Acids. 2005;73(5):379-384.

21.

Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional
foods: Impact on human health. Pharmacognosy reviews. 2010;4(8):118-126.

22.

Hossain SM, ASM Matiur R, Alam MK. PUBLIC HEALTH. Antioxidants in
Combating Morbidities among Underprivileged Preschool Children. International
Medical Journal. 2014;21(3):268-271.

23.

Essa M, Braidy N, Waly M, et al. Impaired antioxidants status and reduced
energy metabolism in autistic children. Research in Autism Spectrum Disorders.
2013:7557-7565.

24.

Dinstein I, Pierce K, Eyler L, et al. Disrupted neural synchronization in toddlers
with autism. Neuron. 2011;70(6):1218-1225.

25.

Rossignol DA, Frye RE. Evidence linking oxidative stress, mitochondrial
dysfunction, and inflammation in the brain of individuals with autism. Front
Physiol. 2014;5:150.

20

26.

Goldani AA, Downs SR, Widjaja F, Lawton B, Hendren RL. Biomarkers in
autism. Front Psychiatry. 2014;5:100.

27.

Vauzour D, Vafeiadou K, Rodriguez-Mateos A, Rendeiro C, Spencer JP. The
neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr.
2008;3(3-4):115-126.

28.

Li S, Chen G, Zhang C, Wu M, Wu S, Liu Q. Research progress of natural
antioxidants in foods for the treatment of diseases. Food Science and Human
Wellness. 2014;3(3):110-116.

29.

Shahidi F, Ambigaipalan P. Phenolics and polyphenolics in foods, beverages, and
spices: Antioxidant activity and health effects-A review. Journal of Functional
Foods. 2015;18:820-897.

30.

Carlsen MH, Halvorsen BL, Holte K, et al. The total antioxidant content of more
than 3100 foods, beverages, spices, herbs and supplements used worldwide. Nutr
J. 2010;9:3.

31.

Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a
semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122(1):5165.

32.

Sokolov AN, Pavlova MA, Klosterhalfen S, Enck P. Chocolate and the brain:
neurobiological impact of cocoa flavanols on cognition and behavior. Neurosci
Biobehav Rev. 2013;37(10 Pt 2):2445-2453.

33.

Smith DF. Benefits of flavanol-rich cocoa-derived products for mental wellbeing: a review. Journal of Functional Foods. 2013;5(1):10-15.

34.

Spencer JP. Flavonoids: modulators of brain function? Br J Nutr. 2008;99 E
Suppl 1:ES60-77.

35.

Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of
oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71(11):956961.

36.

Parisotto EB, Giaretta AG, Zamoner A, et al. Persistence of the benefit of an
antioxidant therapy in children and teenagers with Down syndrome. Res Dev
Disabil. 2015;45-46:14-20.

37.

Crichton GE, Elias MF, Alkerwi A. Chocolate intake is associated with better
cognitive function: The Maine-Syracuse Longitudinal Study. Appetite.
2016;100:126-132.

21

38.

Cooper KA, Donovan JL, Waterhouse AL, Williamson G. Cocoa and health: a
decade of research. Br J Nutr. 2008;99(1):1-11.

39.

Mastroiacovo D, Kwik-Uribe C, Grassi D, et al. Cocoa flavanol consumption
improves cognitive function, blood pressure control, and metabolic profile in
elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study--a randomized
controlled trial. Am J Clin Nutr. 2015;101(3):538-548.

40.

Vauzour D. Dietary polyphenols as modulators of brain functions: biological
actions and molecular mechanisms underpinning their beneficial effects. Oxid
Med Cell Longev. 2012;2012:914273.

41.

Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, Abbott NJ. Flavonoid
permeability across an in situ model of the blood-brain barrier. Free Radic Biol
Med. 2004;36(5):592-604.

42.

Scholey AB, French SJ, Morris PJ, Kennedy DO, Milne AL, Haskell CF.
Consumption of cocoa flavanols results in acute improvements in mood and
cognitive performance during sustained mental effort. J Psychopharmacol.
2010;24(10):1505-1514.

43.

Field DT, Williams CM, Butler LT. Consumption of cocoa flavanols results in an
acute improvement in visual and cognitive functions. Physiol Behav. 2011;103(34):255-260.

44.

Davison K, Berry NM, Misan G, Coates AM, Buckley JD, Howe PR. Doserelated effects of flavanol-rich cocoa on blood pressure. J Hum Hypertens.
2010;24(9):568-576.

45.

Grassi D, Desideri G, Necozione S, et al. Cocoa consumption dose-dependently
improves flow-mediated dilation and arterial stiffness decreasing blood pressure
in healthy individuals. J Hypertens. 2015;33(2):294-303.

46.

Nurk E, Refsum H, Drevon CA, et al. Intake of flavonoid-rich wine, tea, and
chocolate by elderly men and women is associated with better cognitive test
performance. J Nutr. 2009;139(1):120-127.

47.

Shrime MG, Bauer SR, McDonald AC, Chowdhury NH, Coltart CE, Ding EL.
Flavonoid-rich cocoa consumption affects multiple cardiovascular risk factors in a
meta-analysis of short-term studies. J Nutr. 2011;141(11):1982-1988.

48.

Richelle M, Tavazzi I, Enslen M, Offord EA. Plasma kinetics in man of
epicatechin from black chocolate. Eur J Clin Nutr. 1999;53(1):22-26.

22

49.

Heiss C, Finis D, Kleinbongard P, et al. Sustained increase in flow-mediated
dilation after daily intake of high-flavanol cocoa drink over 1 week. J Cardiovasc
Pharmacol. 2007;49(2):74-80.

50.

Nehlig A. The neuroprotective effects of cocoa flavanol and its influence on
cognitive performance. Br J Clin Pharmacol. 2013;75(3):716-727.

51.

Jensen O, Kaiser J, Lachaux JP. Human gamma-frequency oscillations associated
with attention and memory. Trends Neurosci. 2007;30(7):317-324.

52.

Colgin LL, Moser EI. Gamma oscillations in the hippocampus. Physiology.
2010;25(5):319-329.

53.

Castillejo G, Bullo M, Anguera A, Escribano J, Salas-Salvado J. A controlled,
randomized, double-blind trial to evaluate the effect of a supplement of cocoa
husk that is rich in dietary fiber on colonic transit in constipated pediatric patients.
Pediatrics. 2006;118(3):e641-648.

54.

Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of
ascorbic acid as supplemental therapy for autism. Progress in NeuroPsychopharmacology and Biological Psychiatry. 1993;17(5):765-774.

55.

Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled
clinical trial of N-Acetylcysteine added to risperidone for treating autistic
disorders. BMC Psychiatry. 2013;13:196.

56.

Nikoo M, Radnia H, Farokhnia M, Mohammadi MR, Akhondzadeh S. Nacetylcysteine as an adjunctive therapy to risperidone for treatment of irritability
in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy
and safety. Clin Neuropharmacol. 2015;38(1):11-17.

23

CHAPTER 2
ANTIOXIDANTS AND AUTISM: TEACHERS’ PERCEPTIONS OF
BEHAVIORAL CHANGES

*Amy Sadek, Lee S. Berk, Karen Mainess, Noha S. Daher
Amy Sadek, B.S., MOT, OTR/L is a PhD candidate in Rehabilitation Sciences at Loma
Linda University (LLU) in Loma Linda, California. Lee S. Berk, DrPH, is the Associate
Dean of Research Affairs, a full professor in the School of Allied Health, and an
associate research professor in the School of Medicine at LLU, Karen Mainess, PhD SLP
CCC, is an assistant professor in the School of Allied Health Professions, Department
of Communication Sciences and Disorders at LLU, and Noha S. Daher, DrPH, is a full
professor in the School of Allied Health, Department of Statistics and Research at LLU.

24

Abstract
BACKGROUND- Children with Autism Spectrum Disorder (ASD) demonstrate
a physiological imbalance between free radicals, resultant from oxidative stress, and
antioxidants. Oxidative stress is linked to the pathogenesis of this neurocognitive
disorder. The aim of this pilot feasibility study was to examine the effect of consumption
of high concentration antioxidant cacao on behavior of children with ASD.
METHODS- This was a 4-week pre-test post-test experimental pilot study of
high antioxidant cacao and children with ASD. Participants consumed 8 squares (or 16
grams) per day of the dark chocolate which had a concentration of 70% cacao and 30%
organic cane sugar (total antioxidant concentration was 8,320). The two main behavioral
measures were the Aberrant Behavior Checklist- 2nd Edition and the Autism Spectrum
Rating Scale which were completed by the child’s teacher at baseline and end of week
four.
RESULTS- Sixteen participants were recruited for this study. Follow up data was
available on 12 participants (9 males, 3 females, mean age of 10.9 ±3.9 years).
Significant improvements on the Autism Spectrum Rating Scale were noted in
Social/Communication (p=0.03, η2=0.79), Unusual Behaviors (p=0.02, η2=0.70), and
Self-Regulation (p=0.04, η2=0.59). No significant changes were noted on any of the
Aberrant Behavior Checklist-2 subscales (p>.05).
CONCLUSION- Results from this study support the potential therapeutic benefit
of antioxidants in improving social communication, unusual behaviors, and selfregulation behaviors of children with ASD. Further robust randomized controlled trials
are now necessary to elaborate the validity of these findings.
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Introduction
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized
by deficits in social and communication skills, functional impairments across multiple
settings, repetitive and atypical behaviors, as well as self-regulation impairments related
to sensory input from the environment (APA, 2013). According to the Center for Disease
Control and Prevention (CDC), one in 68 children are identified as having ASD with it
being 4.5 times more prevalent in males than females (CDC, 2016). Although the
specific etiology of ASD remains elusive, there are genetic, environmental,
immunological, and oxidative stress influences that are related to the pathogenesis of the
disorder 3,4. Therefore, the complexity and broad spectrum of ASD lends itself to the need
for a variety of interventions and therapies for these children.
Behavioral therapists, speech and language pathologists, and occupational
therapists often work in parallel in both educational and medical settings to provide
therapy for children with ASD 17. Children with ASD often receive these services through
their special education program. Furthermore, it should be noted that both special
education and general education teachers educate students with ASD 10. Evidence based
practices are limited in nature for the ASD population due to the heterogeneous profiles
of the disorder and often times practitioners implement a variety of strategies that have
not been studied in combination 11. Additional barriers for educators and practitioners
include the child’s behaviors which make conducting standardized assessments
challenging to accurately develop goals and treatment plans in the school environment 12.
Overall, there is limited evidence on teachers’ perceptions of ASD behaviors in the
classroom setting.
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The Food and Drug Administration approved two pharmaceutical agents for ASD,
Risperdal and Abilify. Both drugs target maladaptive behaviors and irritability 14,15. In
addition, almost one third of the ASD population are on Selective Serotonin Reuptake
Inhibitor (SSRIs) 14. However, as with any drug, there are associated adverse effects that
include increased appetite, weight gain, dizziness, drooling, drowsiness, fatigue,
vomiting, nasopharyngitis, fever, insomnia, and upper respiratory infections 14,16. Thus,
non-pharmacological lifestyle oriented interventions may compliment traditional
therapies in targeting behavior, mood, and performance issues associated with ASD
without side effects of medication 17.
Due to the heterogeneous nature of ASD severity and behaviors, which can
change over the course of natural development, it is common to see this population
utilizing multiple therapeutic interventions through the medical model, education system,
and through alternative therapies. Common types of CAM used with ASD children
include but are not limited to diet modifications, vitamin and supplement use, digestive
enzymes, music therapy, among others. Complementary and alternative medicine (CAM)
among children and adolescents are often used to address both behavioral and emotional
issues, such as those found in children with ASD 58. Families of children with ASD
typically use CAM therapies and treatments when their child has multiple conditions 59,60.
Parents often use CAM with their ASD children to target the symptomology of mood and
behavior disturbances related to hyperactivity, irritability, and attention skills 60.
Pharmacologically there are only the two aforementioned approved medications for ASD
and thus any other medications prescribed are used to address behaviors related to
maladaptive behaviors, mood, hyperactivity, and the like 61. Thus, there is a need for
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CAM interventions to offset potential adverse effects of pharmaceutical agents while still
targeting some of the core symptoms.
Although the etiology of ASD is multifactorial, research suggests that there are
some neurophysiological differences between individuals with and without ASD 24. For
example, irregularities in neuronal connections have been associated with “cognitive,
social, and sensory behavioral symptoms,” 24. Of particular relevance to the current study
is research on oxidative stress and ASD symptomology. Previous research indicated a
significant increase in oxidative stress markers in children with ASD compared to
matched controls and their non-Autistic siblings 3,20. Furthermore, the severity of autistic
behaviors was positively correlated with oxidative stress markers, whereas antioxidant
levels were negatively correlated with autistic behaviors 3,26.
Oxidative stress can be due to mitochondrial impairment, environmental factors,
metabolic issues, and genetic predisposition in ASD 20. In turn, oxidative stress can also
lead to a cascade of events such as inflammation, damage to cell membranes,
autoimmunity, methylation damage, cell death, and neurological impairments 26. Thus, it
is evident that this lack of sufficient antioxidants creates a plethora of detrimental
physiological outcomes which can contribute to the pathogenesis of ASD.
The human body offers natural intrinsic mechanisms to counter the damaging
effects of free radicals that lead to oxidative stress by producing antioxidants
endogenously by the body 19,62. Oxidative stress biomarkers are particularly noteworthy
as they have the potential to be modulated by means of non-pharmacological
interventions, such as nutritional interventions 29. Antioxidants’ benefits include
improvement of cellular structure, neutralizing free radicals, neuroprotective, anti-
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inflammatory, accumulation in the hippocampus and cortex, and improvement of
vascular endothelial function 27,32.
In the ASD population, several key studies have been conducted looking at
antioxidant intervention relative to behavior change. According to the first identified
study of its kind, researchers examined use of high antioxidant vitamin C providing eight
grams per 70 kilograms per day for 30 weeks and found a reduction in symptom severity
54

. In addition, several randomized trials using N-Acetylcysteine (NAC), an antioxidant

pro-drug, intervention reported significant improvements in irritability, and
hyperactivity/noncompliance subscales on the Aberrant Behavior Checklist (ABC) 35,55,56.
Cacao is a natural and potent antioxidant and is a food rich in flavonoids and their
sub group flavanols. For the purposes of this paper, cacao and cocoa are used
interchangeably. Both flavonoids and flavanols are associated with improved cognitive
processing, alertness, and processing speed 37. Known physiological benefits of cocoa
include improved cardiovascular activity, insulin resistance, blood pressure, endothelial
function, lipid peroxidataion, cognitive response time, enhanced gamma frequency, and
increased cerebral blood flow 27,32,37-39. The aforementioned studies summarize the
inherent value in cacao as a natural superfood for the mind and the body.
The purpose of this study was to examine changes in ASD children’s behavior
following 70% cacao consumption, with a high total antioxidant concentration, over a
four-week period. Changes in behavior were assessed using two behavior scales: ABC-2
and Autism Spectrum Rating Scale (ASRS) 63,64.
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Methods
Study Design
This was a four-week pre-test post-test experimental clinical trial of children with
ASD who consumed high antioxidant cacao, also known as dark chocolate. The study
was conducted in Southern California, United States of America between September
2017 and March 2018. Participants were recruited through snowball sampling techniques
following study approval. This study was approved by the Institutional Review Board at
Loma Linda University and registered in the National Institutes of Health online database
at clinicaltrials.gov (NCT 03195465). Additionally, an Investigational New Drug
application was submitted, however, the application was not deemed mandatory for this
study by the Food and Drug Administration.

Participants
Participants were children with a diagnosis of ASD between the ages of 4 and 18
and their classroom teachers. Sixteen children and their teachers, from 13 different school
districts in Southern California, were recruited. Two teacher participants were excluded
from the analysis due to missing study data, one was not able to provide post-intervention
feedback because of a school break, and one was excluded because the child was home
schooled thus there was no teacher rater available. For subjects’ characteristics, refer to
Table 1.
In order to be eligible for the study, participants had to have a clinical diagnosis of
Autism Spectrum Disorder, be between the ages of four and 18, and like eating dark
chocolate. A taste test was offered to the child at baseline to ensure he/she would be
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willing to eat it daily for four weeks. Participants with food allergies, caffeine
hypersensitivity, theobromine hypersensitivity, a history of seizures or epilepsy, a
developmental age less than 24 months, diabetes, and those who were currently enrolled
in another study were excluded from this study.

Procedures and Interventions
The cacao utilized in this study was analyzed for total antioxidant activity at
Medallion Laboratories in Minnesota. They are considered to be a premiere and
accredited nutraceutical lab that uses scientifically sound analyses on food, dietary
supplements, and pharmaceutical agents. The standardized unit of analysis for total
antioxidant activity is measured in µmoles trolox equivalent (TE) / 100 grams (g) 30. The
antioxidant activity of the cacao used was 52,000 µmoles TE / 100 g. The dark chocolate
used in this study consisted of two ingredients, 70% cacao and 30% organic cane sugar.
Participants in the study consumed eight squares of the dark chocolate, or 16 grams per
day totaling 8,320 µmoles TE / 100 grams. Participants consumed four squares of the
cacao twice daily with the first dose in the morning and the second dose in the afternoon.
Participants consumed their first dose at approximately 8:00 a.m. and their second dose at
approximately 6:00 p.m. depending on the child’s school and sleep schedule. All
participants were asked to be consistent at both times of day for the duration of the study
and logs were kept and collected each week to check for compliance. The cacao was
wrapped in foil, parchment paper, and sealed Ziploc bags to protect it from light and air
so as to prevent oxidation in order to maintain the cacao's antioxidant integrity.
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Measures
The primary outcome measures were the standardized assessment scales:
Aberrant Behavior Checklist 2nd Edition (ABC-2) and the Autism Spectrum Rating Scale
(ASRS). Both scales have been validated and are used to assess behavioral outcomes in
children with ASD 63-65.
The ABC-2 scale consists of five sub-scales which include measures of
Irritability, Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance, and
Inappropriate Speech. The ABC-2 consists of 58 questions with each question ranging
from zero to three; 0 = no problem, 1 = the behavior is not a problem but slight in degree,
2 = the problem is moderately serious, and 3 = the problem is severe in degree 63,66. The
sum of each subscale was calculated and larger subscale totals indicated more severe
behaviors in that category.
The ASRS consists of three subscales which include Social/Communication,
Unusual Behaviors, and Self-Regulation for six to 18 year olds and
Social/Communication and Unusual Behaviors for two to five year olds. The ASRS
consists of 71 questions, with each question ranging from zero to four; 0 = behavior never
happens, 1 = rarely happens, 2 = occasionally happens, 3 = frequently happens, and 4 =
happens very frequently. In other words, the higher the score the more severe the
behaviors for each subscale. Scores from each subscale were calculated using T-Scores in
accordance with the standard scoring technique 64. Teachers filled out both questionnaires
(ABC-2 & ASRS) at baseline and at the end of week four.
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Statistical Analyses
A sample size of 15 subjects was estimated using a medium effect size of 0.70, a
power of 0.80, and a level of significance set at 0.05. Data analysis was performed using
IBM SPSS Statistics Version 25.0. Data was summarized using mean ± standard
deviation for quantitative variables and frequency (%) for categorical variables. The
normality of the outcome variables was examined using Shapiro-Wilk test. Wilcoxon
Signed Rank Test was conducted to compare changes (baseline vs. four weeks later) in
ABC-2 and ASRS scores. Results were considered significant at p ≤ 0.05.

Results
Participant characteristics are reported in Table 1. Twelve children with ASD
with a mean age of 10.9 ± 3.9 participated in the study. Seventy five percent were males
(n = 9) and 42% were White (n = 5). Fifty eight percent of the participants were in a
special day class (n = 7) and seventy five percent were verbal (n = 9). All the participants
were enrolled in an Individualized Education Program. (Table 1)
Child’s medical history and type of therapy are displayed in Table 2. Seventy five
percent of participants had some type of stressful event (parent divorced, changed
schools, parent changed job, family moved, death in family, financial problems).
Approximately 83% sleep, on average, seven or more hours per night. The majority of
the participants either previously received or currently receive speech therapy,
occupational therapy, and applied behavioral analysis. (Table 2)
Changes in ABC-2 and ASRS scores are reported in Table 3. There were no
significant changes in the ABC-2 subscales of Irritability, Social Withdrawal, Stereotypic
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Behavior, Hyperactivity/Noncompliance, and Inappropriate Speech (p >.05). A
significant improvement was noted in Social/Communication (p=0.03, η2=0.79), Unusual
Behaviors (p=0.02, η2=0.70), and Self-Regulation (p=0.04, η2=0.59). (Table 3)

Discussion
In this pilot study, we conducted a pre-test post-test experimental clinical trial to
examine the effects of high antioxidant cacao consumption on behaviors in children with
ASD. Teacher perceptions were recorded as rated on the ABC-2 and ASRS at the
beginning and end of the four-week study. The cacao intervention was well tolerated and
no side effects were reported by any of the participants’ parents over the course of the
intervention. The results of this study indicated that teachers perceived a significant
improvement in their ASD student’s behavior in the ASRS subcategories of: 1)
social/communication, 2) unusual behaviors, and 3) self-regulation. No significant
changes were noted on any of the subscales on the ABC-2. This is particularly
noteworthy as previous antioxidant and ASD studies used the ABC scale and found
improvements in hyperactivity and irritability subscales 35,55,56. A possible explanation for
the difference between the aforementioned studies and this study may be attributed to the
fact that the teacher was the informant since they are trained in objective assessments,
whereas in previous studies a trained rater was the informant. Another possible
explanation could be due to the different time frames used in previous studies conducted
for eight weeks, 10 weeks, 12 weeks and 30 weeks compared to four weeks in the present
study 35,54-56. These investigations suggest the potential behavioral benefits of antioxidant
therapies on ASD as a neurocognitive disorder 35,55,56.
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The effects of antioxidants on behavior and mood in children with ASD is not
well understood and the research is still in its infancy. However, based on the results
from previous literature in adults, the evidence on cocoa appears promising in its
neuroprotective benefits. For example, flavonoids, a subclass of flavanols found in cacao,
have the ability to cross the blood brain barrier which demonstrates their neuroprotective
mechanisms as well as their role in cognitive functions such as learning and memory 34.
Further, consumption of cocoa flavanols (CF) in adults significantly improved scores on
a cognitive battery test and in rapid visual information processing, visual contrast
sensitivity, reduced the time required to detect motion direction, and improved spatial
memory 42,43. Both of these studies noted that while the mechanisms underlying the
effects are still unknown and they may be related to effects of CF on endothelial function
and blood flow which allows improved transfer and delivery of oxygen and nutrients
systemically. In a recent brief review, researchers concluded that consumption of CF
demonstrated improvements in cognitive performance, working memory, attention,
neuroprotective mechanisms, and processing speed 67. The aforementioned studies were
conducted on adult populations including cognitively at risk adults, however, no studies
have been done on school-aged children with ASD 34,42,43,67.
This study had some limitations that include a lack of control group and limited
sample size. Additionally, investigators did not monitor overall nutritional intake
throughout the entirety of the study which means potential confounders in diet could have
impacted validity. The length of the study may have not been sufficient to demonstrate
more significant behavior change in the participants. Due to the pilot feasibility nature of
this study, it was premature to include different intake concentrations of cacao for
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participants as previous literature on adults was inconsistent and limited. All participants
were receiving some form of therapy targeting behavior, communication, and regulation
skills, however, it would be unethical and unrealistic to include ASD children who were
not receiving any type of therapy.
Future studies are recommended so as to conduct an intervention for extended
periods of time and assess changes at multiple time points. Considering analyzing
biomarkers such as, urine or serum blood samples would be supportive and help validate
any physiological changes in antioxidant and free radical status. Comparing different
groups with different amounts of cacao, as well as running a randomized control trial will
help determine if the change was in fact due to the intervention 17. Additionally,
examining behavior changes both through informant based psychometric assessments and
performance based assessments (i.e. motor based tasks, attention tasks) would increase
validity of this novel intervention. Complementary and alternative medicine, or therapies,
are worth examining in the ASD population with consideration of the child’s medical
history, diet history, and efficacy of alternative therapies before their use is recommended
61

. Additionally, biologically based therapies, such as nutrition, are often used as parents

tend to use CAM intervention in an effort to avoid the adverse effects of pharmaceutical
agents 68. Thus, nutrition interventions, such as this study, should continue to be analyzed
as a CAM for the ASD population.

Conclusion
To the authors’ knowledge, to date, this is the first pilot study linking nutritional
antioxidant cacao consumption to behavior in the ASD population from a teacher’s
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perspective. Results from this study support the potential therapeutic benefit of
antioxidants in improving behaviors of children with ASD. Additional robust randomized
controlled trials are needed to further examine and validate these positive outcomes.
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Table 1. Participant characteristics (N = 12).
n
10.9 ± 3.9

%

Gender
Female
Male

3
9

25.0
75.0

Grade
K
1
2
4
5
6
10
12

1
1
1
1
2
3
2
1

8.3
8.3
8.3
8.3
16.7
25.0
16.7
8.3

Class setting
SDC Mild/Moderate
SDC Moderate/Severe
General Education with RSP
General education full inclusion

6
1
2
3

50.0
8.3
16.6
25.0

IEP

12

100.0

Verbal ability
Non verbal
Limited verbal
Verbal

1
2
9

8.3
16.7
75.0

Age (Mean ± SD)

Ethnicity
White
5
41.7
Hispanic or Latino
3
25.0
African American
1
8.3
Mixed ethnicities
3
25.0
*Abbreviations: SDC, Special Day Class; IEP, Individualized Education Program; RSP,
Resource Specialist Program
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Table 2. Child’s medical history and type of therapy (N=12).
n

%

Stressful Event
None
Parent divorced/separated
Parent changed jobs
Parent changed job/changed schools
Family moved/financial problems
Family moved/changed schools
Death in family/parent changed job/changed schools

3
1
2
1
1
2
1

25.0
8.3
16.7
8.3
8.3
16.7
8.3

Headaches

1

8.3

ADHD

4

33.3

Anxiety/Depression

2

16.7

Hours of sleep per day
4-6 hours
7-8 hours
9 hours or more

1
5
5

8.3
41.7
41.7

Medications
ADHD
ADD
Anxiety
Mood Disorder

3
1
2
1

25.0
8.3
16.7
8.3

Type of Therapy
Individual psychotherapy
1
8.3
Group psychotherapy
1
8.3
Family therapy
1
8.3
Speech therapy
11
91.7
Occupational therapy
10
83.3
Applied Behavior Analysis
8
66.7
Physical therapy
3
25.0
Early intervention
8
66.7
Abbreviations: ADHD, Attention Deficit Hyperactivity Disorder; ADD, Attention Deficit
Disorder
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Table 3. Median (min, max) Scores for ABC-2 and ASRS over time.
Scale

Four weeks

p value* (η2)

5.0 (0,31)

6.0 (0,28)

0.27 (0.18)

13.5 (1,33)

9.0 (0,32)

0.48 (0.13)

2.5 (0,15)

3.0 (0,15)

0.61 (0.05)

10.5 (1,36)

8.0 (0,43)

0.20 (0.13)

1.0 (0,9)

0.5 (0,9)

0.59 (0.04)

Baseline

ABC-2
Irritability
Social Withdrawal
Stereotypic Behavior
Hyperactivity/Noncompliance
Inappropriate Speech
ASRS
Social/Communication

63.0 (55,82)

58.5 (47,82)

0.03 (0.79)

Unusual Behaviors

66.5 (58,85)

60.5 (53,81)

0.02 (0. 70)

Self-Regulation

61.0 (51,80)

58.0 (43,83)

0.04 (0.59)

Total of all 3 Subscales T Score
69.5 (62,79) 59.0 (52,79) 0.007 (1.4)
Abbreviations: ABC-2, Aberrant Behavior Checklist 2nd Edition; ASRS, Autism
Spectrum Rating Scale, η2 = effect size
*Wilcoxon Signed Rank Test
Effect Size = mean of difference
SD of the difference
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Abstract
BACKGROUND- Children with Autism Spectrum Disorder (ASD) tend to have
higher free radicals than antioxidants compared to their matched controls. The aim of this
pilot study was to examine the effect of high antioxidant cacao consumption on behavior
in children with ASD.
METHODS- This was a 4-week repeated measures experimental study. Sixteen
participants, aged 4 to 17 years, consumed 8 squares of dark chocolate per day. The
Aberrant Behavior Checklist- 2nd Edition (ABC-2) and the Autism Spectrum Rating Scale
(ASRS), were completed by the parent at baseline, end of week two, and end of week
four.
RESULTS- Significant improvements were noted on the ABC-2 subscales of
Irritability, Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance, and
Inappropriate Speech (p≤0.05) and on the ASRS scales (p≤0.05).
CONCLUSION- Results indicated that antioxidant intake can improve behaviors
of ASD children. More studies are needed to validate these findings.
ClinicalTrials.gov Identifier- NCT 03195465
Key words: antioxidants, cacao, autism, behavior, parents, perceptions
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Introduction
Autism Spectrum Disorder
Autism Spectrum Disorder (ASD) is a life-long neurodevelopmental disorder
characterized by core deficits in communication skills, maladaptive behaviors, and selfregulation impairments related to atypical responses to sensory stimuli in the
environment (APA, 2013). The prevalence of ASD in the United States (U.S.) is reported
at 1 in 68 children with it being four times more common in males than females (CDC,
2016). According to the World Health Organization (2017), worldwide, one in 160
children have ASD. The etiology of ASD is still unknown, however, genetic,
environmental, immunological, and oxidative stress factors are linked to its pathogenesis
3,4

. Additionally, perinatal and neonatal risk factors such as, “abnormal fetal presentation,

umbilical-cord complications, fetal distress, birth injury or trauma, multiple birth,
maternal hemorrhage, summer birth, low birth weight, small for gestational age,” among
others have been identified as part of the association with ASD 5. The heterogeneity of
ASD lends itself to the need for a variety of interventions, both traditional and nontraditional, as no one therapy works across the spectrum.

Conventional Therapies
Occupational therapists, speech therapists, and behavioral therapists are the most
common professionals that work with children with ASD. Occupational therapists
address self-regulation as it relates to sensory dysfunction in the classroom, transitions
between environments, and for task completion in home and school environments 9.
Speech and Language Pathologists work on social interaction, communication skills, and
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alternative communication techniques, among other speech related impediments to
enhance communication (American Speech-Language-Hearing Association, 2006).
Behavioral therapists work with ASD children on aberrant behaviors, language skills,
daily living skills, and social functioning. Applied behavioral analysis (ABA), employs
rote discrete trials in a one on one setting and is an intensive approach that is
recommended up to 40 hours per week 6,7. All three of these intervention approaches are
used in parallel to address ASD children’s performance skills and behavior in both
educational and home environments.
Currently, there are only two Food & Drug Administration (FDA) approved drugs
for ASD, Risperidone and Abilify 14. Risperidone is a second-generation antipsychotic
prescribed for maladaptive behaviors and self-injurious behaviors whereas Abilify treats
mood and irritability 14. Adverse effects include weight gain, dizziness, drooling, fatigue,
vomiting, nasopharyngitis, fever, insomnia, and upper respiratory infections 14,16. Thus,
there is both a place and need for complementary and alternative therapies in addressing
the behavioral symptomology of ASD that impedes on quality of life without some of the
adverse effects of pharmacological agents.
When the aforementioned therapies and pharmaceutical agents are considered, the
cost of ASD becomes colossal. A recent study reported that the cost of ASD in the United
States (U.S.), across one’s lifetime, is $1.4 million and $2.4 million, respectively, if they
also have an intellectual disability 18. However, as with any disability or disorder the cost
is indefinite as there are also psychological and stress costs that cannot be quantified for
the individuals or families caring for them. Lifestyle oriented approaches may, then, be
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necessary not only to potentially offset costs but to improve quality of life in a long term
sustainable fashion.

Oxidative Stress and ASD
Even though ASD’s etiology is multifactorial and still unknown, research
suggests there may be neuron irregularity, between those with and without ASD, that is
linked to the classic behavioral and social symptoms 24. Oxidative stress, an imbalance
between antioxidants and free radicals, is of significance to this study and has been linked
to the pathogenesis of ASD. Damodaran, Arumugam 3 found a significant increase in
oxidative stress markers in children with ASD compared to matched controls and the
severity of maladaptive behaviors were positively correlated with free radicals while
antioxidants were negatively correlated with autistic behaviors 3,26. In addition, elevated
blood samples of glutathione, glutathione peroxidase, methionine, oxidized glutathione,
and cysteine have also been found in children with ASD 26. These studies, although
limited in number, suggest that the excess of free radicals may be linked to adverse
behavioral outcomes.
Ming, Stein, Brimacombe, Johnson, Lambert, Wagner 20 suggests that children
with ASD tend to have greater markers of oxidative stress compared to age matched
controls or their non-Autistic siblings. Oxidative stress may be related to mitochondrial
impairment, environmental factors, metabolic issues, and genetic predisposition (Ming et
al., 2005). Inflammation, damage to cellular membranes, autoimmunity, methylation
damage, cell death, and neurological impairments are all resultant of free radical damage
26

. Oxidative stress can be identified through markers of antioxidant enzymes, lipid
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peroxidation, and protein oxidation, all of which are higher in children with autism
compared to their matched controls 3,20. In summary, the above studies support emerging
evidence on the physiological differences in oxidative stress between children with ASD
and those without, creating detrimental biological and behavioral outcomes.
Our bodies have an innate mechanism to endogenously produce antioxidants to
counter the deleterious effects of free radicals caused by oxidative stress 19,62. However,
when these mechanisms are out of balance we may need to consider nutritional options to
supplement these deficits. Antioxidants benefit us physiologically by maintaining cellular
integrity, combating free radicals, and improving vascular function while also offering
neuroprotection by accumulating in the hippocampus and cortex 27,32. As a result,
antioxidants may be beneficial and necessary to provide homeostasis to oxidative stress
imbalance, as seen in ASD.
To date, a few important studies examined the effects of antioxidant intervention
relative to behavior change in the ASD population. Dolske, Spollen, McKay, Lancashire,
Tolbert 54 appear to be the first researchers to examine antioxidant therapy, in the form of
Vitamin C, providing eight grams per 70 kilograms of body weight per day in 500
milligram (mg) tablets for 30 weeks and found a reduction in autistic symptom severity.
Additionally, randomized controlled trials using N-Acetylcysteine (NAC), an antioxidant
pro-drug, intervention found significant improvements in the irritability and
hyperactivity/noncompliance subscales on the Aberrant Behavior Checklist (ABC) 35,55,56.
Cacao is a natural and potent antioxidant. For the purposes of this paper, cacao
and cocoa are used interchangeably. Flavonoids and flavanols, subclasses of antioxidants
found in cacao, have been correlated with improved cognitive processing, alertness, and
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processing speed 37. Cocoa’s physiological and neurological benefits are vast and include
improved cardiovascular activity, insulin resistance, blood pressure, lipid peroxidation,
enhanced gamma frequency, and increased cerebral blood flow 27,32,37-39. Additionally,
cocoa protects neurons from apoptosis, promotes angiogenesis, and thus leads to more
optimal brain functioning which enhances delivery and receipt of oxygen and nutrient
supply 50. The aforementioned studies summarize the inherent value in cacao as a natural
functional food for the mind and the body which may be of significant value to
neurocognitive disorders, such as ASD.
The purpose of this study was to examine changes in ASD children’s behavior
following dark chocolate consumption, over a four-week period. Behavioral changes
were assessed by each child’s parent using two behavior scales: Aberrant Behavior
Checklist 2nd Edition (ABC-2) and Autism Spectrum Rating Scale (ASRS) 63,64.

Methods
Study Design
This was a four-week repeated measures experimental pilot study and clinical trial
of children with ASD who consumed high antioxidant cacao, or dark chocolate. The
study was conducted in Southern California, United States of America, between
September 2017 and March 2018. Recruitment of participants through snowball sampling
techniques was initiated following study approval. This study was approved by the
Institutional Review Board at Loma Linda University and was registered in the National
Institutes of Health online database at clinicaltrials.gov (NCT 03195465). An
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Investigational New Drug application was submitted to the Food and Drug
Administration, however, was not required for the study.

Participants
Participants were children with a diagnosis of ASD, between the ages of 4 and 17,
and their parents. Seventeen children and their parents were recruited. One participant
dropped leaving a total sample of sixteen with follow up data. For subjects’
characteristics, refer to Table 1. In order to be eligible for the study, participants had to
have a diagnosis of Autism Spectrum Disorder, be between the ages of four and 18, and
like eating dark chocolate. A taste test was offered to the child at baseline to ensure
he/she would be willing to eat it daily for four weeks. Participants with food allergies,
caffeine hypersensitivity, theobromine hypersensitivity, a history of seizures or epilepsy,
a developmental age less than 24 months, diabetes, and those who were currently
enrolled in another study were excluded from this study.

Procedures and Interventions
The cacao utilized in this study was analyzed for total antioxidant activity at
Medallion Laboratories in Minnesota. Medallion Labs are considered to be a premiere
and accredited nutraceutical lab that use scientifically sound analyses on food, dietary
supplements, and pharmaceutical agents. The standardized unit of analysis for total
antioxidant activity is measured in µmoles trolox equivalent (TE) / 100 grams (g) 30. The
antioxidant activity of the cacao used was 52,000 µmoles TE / 100 g. The dark chocolate
used in this study consisted of two ingredients, 70% cacao and 30% organic cane sugar.
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Participants in the study consumed eight squares of the dark chocolate, or 16 grams per
day totaling 8,320 µmoles TE / 100 grams. Participants consumed four squares of the
cacao twice daily with the first dose in the morning and the second dose in the afternoon,
or early evening. All participants were asked to be consistent at both times of day for the
duration of the study and logs were kept and collected each week to assess compliance.
The cacao was wrapped in parchment paper and foil, then sealed in Ziploc bags to protect
it from light and air to prevent oxidation in order to maintain the cacao’s antioxidant
integrity.

Measures
The primary outcome measures were the Aberrant Behavior Checklist 2nd Edition
(ABC-2) and the Autism Spectrum Rating Scale (ASRS). Both scales have been
validated and used to assess behavioral outcomes in children with ASD 63-65.
The ABC-2 measures behaviors in populations with developmental delays and is
traditionally administered on children ages five and older, however, permissions were
obtained from the developer to administer to ages four and older 63. The ABC-2 scale
consists of five sub-scales including, Irritability, Social Withdrawal, Stereotypic
Behavior, Hyperactivity/Noncompliance, and Inappropriate Speech. The ABC-2 has 58
questions with scores ranging from zero to three; 0 = no problem, 1 = the behavior is not
a problem but slight in degree, 2 = the problem is moderately serious, and 3 = the
problem is severe in degree 63,66. Subscale sums were calculated and larger subscale totals
indicated more severe behaviors in that category.
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The ASRS consists of three scales which include Social/Communication, Unusual
Behaviors, and Self-Regulation for six to 18 year olds and Social/Communication and
Unusual Behaviors for two to five year olds. The ASRS has 71 questions, with scores
ranging from zero to four; 0 = behavior never happens, 1 = rarely happens, 2 =
occasionally happens, 3 = frequently happens, and 4 = happens very frequently. In other
words, the higher the score the more severe the behaviors for each scale. Scores from
each scale were calculated using T-Scores in accordance with the standard scoring
technique 64. Parents filled out the ABC-2 & ASRS at baseline, end of week two, and end
of week four.

Statistical Analyses
A sample size of 15 subjects was estimated using a medium effect size of 0.70, a
power of 0.80, and a level of significance set at 0.05. Data analysis was performed using
IBM SPSS for Windows Version 25.0. Data was summarized using mean ± standard
deviation for quantitative variables and frequency (%) for categorical variables. The
normality of the outcome variables was examined using Shapiro-Wilk test. Friedman’s
test was conducted to determine overall change over time. Wilcoxon Signed Rank test
was used to compare changes between different time points (baseline vs. two weeks;
baseline vs. four weeks; two weeks vs. four weeks) in ABC-2 and ASRS scores. Results
were considered significant at p ≤ 0.05.
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Results
Participant characteristics are reported in Table 1. Sixteen children with ASD with
a mean age of 11.1 ± 3.6 participated in the study. Seventy-five percent were males (n =
12), 31% were White (n = 5), and 25% were Hispanic or Latino (n = 4). A majority of
participants were enrolled in an Individualized Education Program (n =15, 93.8%) and
were verbal (n = 11, 68.8%). Forty-four percent of parents worked full time (n = 7), 62%
had a college degree (n = 10), 62% reported an income of $75,000 or higher (n = 9), and
81% were married (n = 13). (Table 1)
Child’s medical history and type of therapy are displayed in Table 2. Twenty-five
percent of participants had ADHD (n = 4) and were taking medication for attention
related issues (n = 4). Approximately 56% sleep, on average, seven or more hours per
night (n = 9). The majority of participants either previously received or were concurrently
receiving speech therapy, occupational therapy, and applied behavioral analysis. (Table
2)
Changes in ABC-2 and ASRS scores are reported in Table 3. Friedman’s test
results showed there were significant improvements over time in the ABC-2 subscales of
Irritability (p=.03, η2 = 0.25), Social Withdrawal (p=.01, η2 = 0.29), Stereotypic Behavior
(p=.05, η2 = 0.13), and Hyperactivity/Noncompliance (p=.04, η2 = 0.20). However, no
significant difference was noted for Inappropriate Speech (p=.22, η2 = 0.16). Friedman’s
test also showed a significant improvement in all ASRS subscales including
Social/Communication (p=.04, η2 = 0.25), Unusual Behaviors (p=.003, η2 = 0.20), SelfRegulation (p=0.02, η2=0.32), and Total Scores (p<.001, η2=0.54). (Table 3)
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Post-hoc comparisons revealed that there was a significant difference in
Irritability between baseline and week four (p =0.035) and between week two and week
four (p=0.014). For Social Withdrawal, a significant difference was found between
baseline and week two (p=0.03) and baseline and week four (p=0.023). A significant
difference was found in Stereotypic Behavior between baseline and week four (p=0.05)
and between week two and week four (p=0.04). Finally, there was a significant
improvement in median Hyperactivity/Noncompliance scores between baseline and week
four (p=0.035). No significant difference was found in median scores for Inappropriate
Speech over time (p=0.22).
In terms of ASRS scales, a significant difference was found in
Social/Communication between baseline and week two (p =0.009) and between baseline
and week four (p =0.026). A significant difference was found in Unusual Behaviors
between baseline and week two (p = 0.022) and baseline and week four (p =0.001). There
was a significant difference in Self-Regulation between baseline and week two (p=0.018)
and baseline and week four (p=0.012). Overall, there was a significant difference in
median Total scores on the ASRS between baseline and week two (p=0.002), baseline
and week four (p=0.002), and between week two and week four (p=0.02). (Table 3)

Discussion
In this pilot study, a repeated measures experimental clinical trial was conducted
to examine the effects of high antioxidant cacao consumption on behaviors in children
with ASD. Overall, participant characteristics revealed that parents were well educated,
of an above average socioeconomic status, and children came from a stable home as most
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were married. A previous study indicated that parents of children with ASD, who are
more educated and affluent, tend to try alternative therapies and enroll their children in
clinical trials more than others 70.
Based on parental report, the dark chocolate was well tolerated and no allergic
reactions were reported over the course of the intervention. The results of this study
indicated that parents perceived a significant improvement in their ASD child’s behavior
in the ASRS scales of: 1) Social/Communication, 2) Unusual Behaviors, and 3) SelfRegulation. Significant improvements were also noted on the ABC-2 subscales of 1)
Irritability, 2) Social Withdrawal, 3) Stereotypic Behavior, and 4)
Hyperactivity/Noncompliance. Overall, median scores decreased, indicating that
participants were less irritable, socially withdrawn, and reduced stereotypic behaviors. In
addition, participants improved in their social/communication skills and self-regulation,
and had less unusual behaviors. The results of this study are consistent with the findings
from the NAC and ASD studies that found improvements in hyperactivity and irritability
ABC-2 subscales 35,55,56. Based on these studies, there is promising benefit of antioxidantbased therapies in targeting common behavioral symptoms in ASD 35,55,56.
Although there is limited research on antioxidants, specifically cacao, and the
autistic population, previous literature on adults suggests the neuroprotective benefits of
cacao. In recent reviews, the benefits of the cocoa bean and its derivatives were
associated with improved cerebrovascular function, permeation of the blood brain barrier
via flavanols’ (epicatechin and catechin), working memory, attention, processing speed,
and learning 50,67. Furthermore, ingestion of cocoa flavanols (CF) in adults significantly
improved cognitive scores, visual information processing, visual contrast sensitivity, and
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spatial memory 34,42,43. The above studies acknowledge that the underlying mechanisms
of cocoa on brain health are still under investigation, however, observed benefits may be
related to effects on endothelial function and blood flow which promote oxygen and
nutrient delivery systemically. Although the research available on cocoa’s physiological
and neurological benefit for adults is useful there is still a gap in the literature on how
cocoa can be used in the pediatric population, specifically those with neurocognitive
disorders.
Our study had some limitations. First, a lack of control group limits the
generalizability of these results. Second, our assessments, although validated and reliable,
were self-report measures which may include biases. However, previous research
suggests the impact that ASD behaviors have on the parent and so their observations of
behavior change may be most accurate as they understand the intricacies of their child’s
maladaptive behaviors 13. Behaviors associated with ASD not only affect the parent child
dynamic but also dually stress both the parent and child individually 13. Additionally,
parents may be strong raters because their stress has been correlated with the severity of
their child’s behaviors so if behaviors are more or less severe they would be directly
impacted and thus able to report changes 71. Thirdly, nutritional intake was not monitored
over the course of the study which means dietary confounders could have impacted
results. In an attempt to control for dietary effects, we avoided starting participants near
major holiday breaks, such as Christmas and Thanksgiving, where diet may change more
drastically. Fourth, the study length may not have been enough to show more significant
behavior change in the participants. Previous antioxidant studies used different study
lengths ranging from eight weeks, 10 weeks, 12 weeks, and up to 30 weeks compared to
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four weeks in the present study 35,54-56. The results of this study demonstrated an overall
improvement in four of five ABC-2 subscales and all three ASRS scales with the most
significant changes being after two weeks of intervention. Without a control group, it is
difficult to rule out the potential for a placebo effect. However, some of the nonsignificant findings between baseline and week two strengthens the interpretation of
results by suggesting that the significant effects observed after two weeks may not simply
be driven by parents’ belief but an actual intervention effect on behavior.
A major strength of the present study was the low attrition rate since only one
participant withdrew from the study. Previous antioxidant and ASD studies did not
mention total antioxidant activity of interventions used nor was amount of NAC based on
anthropometric assessments of individual participants 35,54-56. Thus, another strength of
the present investigation is the analysis and report of total antioxidant activity of the
cacao validating its use as an antioxidant intervention. It should be noted that because this
was a pilot feasibility study, it seemed premature to include different intake
concentrations of cacao for participants as previous literature on adults was inconsistent
and limited. However, future studies may want to consider offering different
concentrations based on body weight as nutritional needs differ across the lifespan. All
participants were receiving one or more traditional therapies targeting core symptoms,
however, it would be unethical and unrealistic to include ASD children who were not
receiving any type of therapy.
Future studies are recommended to run the intervention for longer time periods
and measure changes throughout the study to determine when the effect occurs. Analysis
of biomarkers including urine or serum blood samples will be imperative to determine
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any physiological changes in oxidative stress status. Comparing groups using different
concentrations of cacao based on anthropometric assessments, such as weight, through
randomized controlled trials will further validate if observed changes are in fact due to
the antioxidant intervention. Complementary and alternative medicine (CAM) need to be
researched to determine efficacious approaches in the ASD population with consideration
of the child’s medical history and diet history before recommendations can be made 61.
Biologically based therapies, including nutraceuticals, are commonly employed by
parents of children with disabilities because CAM interventions do not have the same
adverse side effects as pharmaceutical interventions 68. Thus, nutrition interventions,
more specifically antioxidant therapies, as used in this study, need to remain under
investigation as a potential CAM for addressing and hopefully improving ASD
behavioral symptoms.

Conclusion
To the authors’ knowledge, to date, this is the first pilot study associating
consumption of a nutraceutical, high antioxidant cacao, to behavioral outcomes in the
ASD population from a parent’s perspective. Results from this study add to the existing
literature on the potential benefits of antioxidants on improving behavior in children with
ASD. Further robust randomized controlled trials are needed to further validate these
positive findings.
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Table 1. Participant characteristics (N=16).
n
11.1 ± 3.6

%

Male

12

75.0

Grade
K
1
2
4
5
6
7
9
10
12

2
1
1
1
2
3
2
1
2
1

12.5
6.3
6.3
6.3
12.5
18.8
12.5
6.3
12.5
6.3

Verbal ability
Non-verbal
Limited verbal
Verbal

3
2
11

18.8
12.5
68.8

Ethnicity
White
Hispanic or Latino
Black or African American
Asian
Native Hawaiian
Mixed ethnicity

5
4
1
1
1
4

31.3
25.0
6.3
6.3
6.3
25.0

Diagnosed by
Pediatrician
Neurologist
Inland Regional Center
Psychologist

4
5
5
2

25.0
31.3
31.3
12.5

Employment
Full time
Part time
Out of work and looking
Home maker
Out of work not looking

7
3
1
4
1

43.8
18.8
6.3
25.0
6.3

Age (Mean ± SD)
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Table 1. Continued
n
n

%
%

1
2
3
6
4

6.3
12.5
18.8
37.5
25.0

Income
$20,000-$34,999
$35,000-$49,999
$50,000-$74,999
$75,000-$149,999
$100,000-$149,999
$150,000 or more

2
2
2
4
5
1

12.5
12.5
12.5
25.0
31.3
6.3

Marital status
Single
Married
Divorced
Separated

1
13
1
1

6.3
81.3
6.3
6.3

Custodya
Mother
Shared

2
1

12.5
6.3

Education
Some HS
Some college
Associate’s degree
Bachelor’s degree
Master’s degree

Abbreviations: SDC, Special Day Class; IEP, Individualized Education Program; RSP,
Resource Specialist Program
a
Percentages do not add to 100% because parents are married
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Table 2. Child’s medical history and type of therapy (N=16).
n (%)
Headaches

2 (12.5)

ADHD

4 (25.0)

Anxiety/Depression

3 (18.8)

Sleeping Disorder

1 (6.3)

Hours of sleep per night
4-6 hours
7-8 hours
9 hours or more

2 (12.5)
9 (56.2)
5 (31.3)

Medications
Attention
Anxiety
Mood Disorder
Headache
Behavior

4 (25.0)
3 (18.8)
2 (12.5)
1 (6.3)
3 (18.8)

Type of Therapy
Individual psychotherapy
Group psychotherapy
Family therapy
Speech therapy
Occupational therapy
Applied Behavior Analysis
Physical therapy
Early intervention

1 (6.3)
2 (12.5)
1 (6.3)
15 (93.7)
14 (87.5)
11 (68.8)
4 (25.0)
11 (68.8)

Abbreviations: ADHD, Attention Deficit Hyperactivity Disorder
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Table 3. Median (min, max) Scores for ABC-2 and ASRS over time.
Baseline

Week 2

Week 4

P value* (η2)

Irritability

13.0 (0,35)

13.0 (0,31)

7.0 (0,34)

p= .03, η2 = 0.25

Social Withdrawal

13.0 (1,34)

9.0 (0.37)

7.5 (0,34)

p=.01, η2 = 0.29

3.5 (0,15)

3.0 (1,14)

1.0 (0,16)

p=.05, η2 = 0.13

15.0(4,42)

12.0 (2,39)

9.5 (0,42)

p=.04, η2 = 0.20

3.0 (0,9)

2.0 (0,9)

1.5 (0,10)

p=.22, η2 = 0.16

Social/Communication

70.0 (58,85)

65.5 (52,82)

68.0 (43,85)

p=.04, η2 = 0.25

Unusual Behaviors

69.0 (45,83)

66.0 (7,74)

61.0 (43,74)

p=.003, η2 = 0.20

Self-Regulation

65.0 (48,76)

64.0 (47,75)

60.0 (38,77)

p=.02, η2 = 0.32

Total of 3 Subscales T Score

72.0 (54,83)

68.5 (50,77)

62.0 (45,79)

p<.001, η2 = 0.54

Scale
ABC-2

Subscale

Stereotypic Behavior
Hyperactivity/Noncompliance
Inappropriate Speech
ASRS

Abbreviations: ABC-2, Aberrant Behavior Checklist 2nd Edition; ASRS, Autism Spectrum Rating Scale, η2
= effect size
*Friedman Test
** d η2 = Treatment Sum of Squares
Total Sum of Squares
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CHAPTER 4
DISCUSSION

In this pilot study, we conducted a prospective experimental clinical trial to
examine the effects of high antioxidant cacao consumption on behaviors in children with
Autism Spectrum Disorder. Teacher perceptions were recorded as rated on the Aberrant
Behavior Checklist-2 (ABC-2) and Autism Spectrum Rating Scale (ASRS) at the
beginning and end of the four-week study. The cacao intervention was well tolerated and
no side effects were reported by any of the participants’ parents over the course of the
intervention. The results of this study indicated that teachers perceived a significant
improvement in their ASD student’s behavior in the ASRS scales of: 1)
social/communication, 2) unusual behaviors, and 3) self-regulation. No significant
changes were noted on any of the subscales on the ABC-2. The results of this study
indicated that parents perceived a significant improvement in their ASD child’s behavior
in the ASRS scales of: 1) Social/Communication, 2) Unusual Behaviors, and 3) SelfRegulation. Significant improvements were also noted on the ABC-2 subscales of 1)
Irritability, 2) Social Withdrawal, 3) Stereotypic Behavior, and 4)
Hyperactivity/Noncompliance. Overall, median scores decreased, indicating that
participants were less irritable, socially withdrawn, and reduced stereotypic behaviors. In
addition, participants improved in their social/communication skills and self-regulation,
and had less unusual behaviors. The results of this study are consistent with the findings
from the N-Acetylcysteine (NAC) and ASD studies that found improvements in
hyperactivity and irritability ABC-2 subscales 35,55,56. Based on these studies, there is
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promising benefit of antioxidant-based therapies in targeting common behavioral
symptoms in ASD 35,55,56.
Overall, participant characteristics revealed that parents were well educated, of an
above average socioeconomic status, and children came from a stable home as most
parents were married. A previous study indicated that parents of children with ASD, who
are more educated and affluent, tend to try alternative therapies and enroll their children
in clinical trials more than others 70.
Although there is limited research on antioxidants, specifically cacao, and the
autistic population, previous literature on adults suggests the neuroprotective benefits of
cacao. In recent reviews, the benefits of the cocoa bean and its derivatives were
associated with improved cerebrovascular function, permeation of the blood brain barrier
via flavanols (epicatechin and catechin), working memory, attention, processing speed,
and learning 50,67. Furthermore, ingestion of cocoa flavanols in adults significantly
improved cognitive scores, visual information processing, visual contrast sensitivity, and
spatial memory 34,42,43. The above studies acknowledge that the underlying mechanisms
of cocoa on brain health are still under investigation, however, observed benefits may be
related to effects on endothelial function and blood flow which promote oxygen and
nutrient delivery systemically. Although the research available on cocoa’s physiological
and neurological benefit for adults is useful, there is still a gap in the literature on how
cocoa can be used in the pediatric population, specifically those with neurocognitive
disorders.
Our study had some limitations. First, a lack of control group limits the
generalizability of these results. Second, our assessments, although validated and reliable,
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were self-report measures which may include biases. However, previous research
suggests the impact that ASD behaviors have on the parent and so their observations of
behavior change may be most accurate as they understand the intricacies of their child’s
maladaptive behaviors 13. Behaviors associated with ASD not only affect the parent child
dynamic but also dually stress both the parent and child individually 13. Additionally,
parents may be accurate raters because their stress has been correlated with the severity
of their child’s behaviors so if behaviors are more or less severe they would be directly
impacted and thus able to report changes 71. Thirdly, nutritional intake was not monitored
over the course of the study which means dietary confounders could have impacted
results. In an attempt to control for dietary effects, we avoided enrolling participants near
major holiday breaks, such as Christmas and Thanksgiving, where diet may change more
drastically. Fourth, the study length may not have been enough to show more significant
behavior change in the participants. Previous antioxidant studies used different study
lengths ranging from eight weeks, 10 weeks, 12 weeks, and up to 30 weeks compared to
four weeks in the present study 35,54-56. Furthermore, the results of this study
demonstrated an overall improvement in four of five ABC-2 subscales and all three
ASRS scales with the most significant changes being after two weeks of intervention.
Without a control group, it is difficult to rule out the potential for a placebo effect.
However, some of the non-significant findings between baseline and week two
strengthens the interpretation of results by suggesting that the significant effects observed
after two weeks may not simply be driven by parents’ belief but an actual intervention
effect on behavior.
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A major strength of the present study was the low attrition rate since only one
participant withdrew from the study. Previous antioxidant and ASD studies did not
mention total antioxidant activity of interventions used nor was amount of NAC based on
anthropometric assessments of individual participants35,54-56. Thus, another strength of the
present investigation is the analysis and report of total antioxidant activity of the cacao
validating its use as an antioxidant intervention. It should be noted that because this was a
pilot feasibility study, it seemed premature to include different intake concentrations of
cacao for participants as previous literature on adults was inconsistent and limited.
However, future studies need to consider offering different antioxidant concentrations
based on body weight as nutritional needs differ across the lifespan. All participants were
receiving one or more traditional therapies targeting core symptoms, however, it would
be unethical and unrealistic to include ASD children who were not receiving any type of
therapy.
Future studies are recommended to run the intervention for longer time periods
and measure changes throughout the study to determine when the effect occurs. Analysis
of biomarkers including urine or serum blood samples will be imperative to determine
any physiological changes in oxidative stress status. Comparing groups using different
concentrations of cacao based on anthropometric assessments, such as weight, through
randomized controlled trials will further validate if observed changes are in fact due to
the antioxidant intervention.
Complementary and alternative medicine (CAM) need to be researched to
determine efficacious approaches in the ASD population with consideration of the child’s
medical history and diet history before recommendations can be made61. Biologically
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based therapies, including nutraceuticals, are commonly employed by parents of children
with disabilities because CAM interventions do not have the same adverse side effects as
pharmaceutical interventions68. Thus, nutrition interventions, more specifically
antioxidant therapies, as used in this study, need to remain under investigation as a
potential CAM for addressing and hopefully improving ASD behavioral symptoms.

Conclusion
To the authors’ knowledge, to date, this is the first pilot study associating
consumption of a nutraceutical, high antioxidant cacao, to behavioral outcomes in the
ASD population from both parent and teacher perspectives. Results from both studies add
to the existing literature on the potential benefits of antioxidants on improving behavior
in children with ASD. Further robust randomized controlled trials are needed to further
validate these findings.
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APPENDIX A
PARENT INFORMED CONSENT FORM

INFORMED CONSENT (Parent)

TITLE:

THE EFFECT OF HIGH ANTIOXIDANT CACAO
ON BEHAVIORS IN CHILDREN WITH AUTISM
SPECTRUM DISORDER

SPONSOR:

School of Allied Health Professions, Loma Linda
University

PRINCIPAL
INVESTIGATOR

Lee Berk, DrPH, Associate Dean for Research Affairs

CO-INVESTIGATOR

Amy Sadek, Rehabilitation Science PhD Candidate

WHY IS THIS STUDY BEING DONE?
This study is to see if eating cacao changes Autistic behaviors in children.
Your child can be in this study if you understand and read English and you are 18 years
of age or older, and your child has autism and is between 5-12 years old. Your child must
like 70% cacao and not be allergic.
Children with food allergies, caffeine hypersensitivity, theobromine hypersensitivity, a
history of seizures or epilepsy, a developmental age less than 24 months, or diabetics
cannot be in this study.
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Approximately 35 subjects will participate in this study.
This study may last up to 4 weeks with 5 visits at your child’s school for approximately
30 minutes per visit. The first visit will take up to an hour for all paperwork and initial
questionnaires.
HOW WILL I BE INVOLVED?
This study involves the following:
 When you come for the study, we will obtain informed consent for you and your
child to be in the study.
 You will explain to your child their level of involvement in a manner they can
understand to the best of their ability.
 Your child will also be offered a taste testing sample of the chocolate bar to be
used in the study to see if they like it as that is a requirement to be included in the
study.
 On day one, you will fill out a Food Frequency Questionnaire based on your
child’s typical dietary habits, an Autism Spectrum Rating Scale, an Aberrant
Behavior Checklist, and the Parental Stress Index Questionnaire.
 The Food Frequency Questionnaire asks how often your child consumes foods
like bread, meat, sweets, vegetables, and fruit. The Autism Spectrum Rating Scale
asks questions about play skills, social interaction skills, communication skills,
rigid behaviors, and understanding of humor. The Aberrant Behavior Checklist
asks questions about your child’s irritability, agitation, crying, social behavior,
repetitive behaviors, speech, and hyperactivity. The Parental Stress Index asks
questions about how you’re feeling as a parent, your child’s behavior, and your
interaction with them.
 Your child will consume 3 squares of the 70% dark chocolate every four hours
daily for four weeks during waking hours between 8:00 a.m. and 8:00 p.m.
 You will fill out the Autism Spectrum Rating Scale and the Aberrant Behavior
Checklist at the end of week two and at the end of week four.
 You will fill out the Parental Stress Index Questionnaire at the end of week four.
 Your child’s special education teacher will also fill out the Autism Spectrum
Rating Scale and the Aberrant Behavior Checklist at the beginning of week 1, end
of week 2, and end of week 4. They will also give any doses of the cacao that are
during school hours.
WHAT ARE THE REASONABLY FORESEEABLE RISKS OR DISCOMFORTS
I MIGHT HAVE?
This study poses no greater risk to you than what you routinely encounter in day-to-day
life. Participating in this study will involve the following risks: possible breach of
confidentiality and feeling uncomfortable answering questions about parental stress.
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All records and research materials that identify you and your child will be held confidential.
Any published document resulting from this study will not disclose your identity without
your permission. Information identifying you will only be available to the study personnel.
All data will be secured in a locked cabinet in a locked office.
The use of your Protected Health Information is explained in the separate authorization
form.
WILL THERE BE ANY BENEFIT TO ME OR OTHERS?
Although you may not personally benefit from this study, your participation may help
clinicians and teachers when working with autistic children.
WHAT ARE MY RIGHTS AS A SUBJECT?
Your participation in this study is entirely voluntary. You may refuse to participate or
withdraw once the study has started. Your decision whether or not to participate or
terminate at any time will not affect your future standing with the researchers, the schools,
or the Inland Empire Autism Assessment Center of Excellence. You do not give up any
legal rights by participating in this study.
If, at any time, you feel uncomfortable with the questions on the surveys, you may refuse
to answer questions.
WHAT COSTS ARE INVOLVED?
There is no cost to you for participating in this study.
WILL I BE PAID TO PARTICIPATE IN THIS STUDY?
You will be paid a $50 gift card for completing this study in full.
WHO DO I CALL IF I HAVE QUESTIONS?
You may call 909-558-4647 or e-mail patientrelations@llu.edu for information and
assistance with complaints or concerns about your rights in this study.
SUBJECT’S STATEMENT OF CONSENT
 I have read the contents of the consent form and have listened to the verbal
explanation given
by the investigator.
 My questions concerning this study have been answered to my satisfaction.
 This study has been explained to my child at a level she/he can comprehend and I
give
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permission for my child to participate in the study.
 Signing this consent document does not waive my rights nor does it release the
investigators,
institution or sponsors from their responsibilities.
 I may call Dr. Lee Berk during routine office hours at (909) 651-5828 (ext: 15828) if
I have
additional questions.
 I hereby give voluntary consent to participate in this study.
I understand I will be given a copy of this consent form after signing it.

Signature of Parent/Guardian

Printed Name of Parent/Guardian

Date

Name of Child

Authority to act for subject:____________________________________________
INVESTIGATOR’S STATEMENT
I have reviewed the contents of this consent form with the person signing above. I have
explained potential risks and benefits of the study.

Signature of Investigator

Printed Name of Investigator

Date
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APPENDIX B
SPECIAL EDUCATION TEACHER INFORMED CONSENT

INFORMED CONSENT (Special Education Teacher)
TITLE:

SPONSOR:
PRINCIPAL
INVESTIGATOR:
CO-INVESTIGATOR:

THE EFFECT OF HIGH ANTIOXIDANT CACAO ON
BEHAVIORS IN CHILDREN WITH AUTISM
SPECTRUM DISORDER
School of Allied Health Professions
Lee Berk, DrPH, Associate Dean for Research Affairs
Amy Sadek, Rehabilitation Science PhD Candidate

WHY IS THIS STUDY BEING DONE?
The purpose of the study is to determine if consuming high antioxidant cacao changes the
severity of Autistic behaviors.
You are invited to be in this study because you are an English-literate special education
teacher, 18 years of age or older. We enrolled a child you are teaching in our study and
need your feedback.
Approximately 35 subjects will participate in this study.
This study may last up to 4 weeks with 5 visits at your school site for approximately 30
minutes per visit.
HOW WILL I BE INVOLVED?
Participation in this study involves the following:
 Following your school districts’ agreement to participate, we will obtain informed
consent from you.
 On day one, you will fill out an Autism Spectrum Rating Scale and an Aberrant
Behavior Checklist for the child.
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Your student who is autistic will consume 3 squares of the 70% dark chocolate
every four hours daily for four weeks during waking hours between 8:00 a.m. and
8:00 p.m.
You will provide the doses that occur during school hours such as 8:00 a.m. and
12:00 p.m.
You will fill out the Autism Spectrum Rating Scale and the Aberrant Behavior
Checklist at the end of week two and at the end of week four.

WHAT ARE THE REASONABLY FORESEEABLE RISKS OR DISCOMFORTS
I MIGHT HAVE?
This study poses no greater risk to you than what you routinely encounter in day-to-day
life. Participating in this study will involve the following risks: possible breach of
confidentiality and feeling uncomfortable answering questions.
All records and research materials that identify you and the child will be held confidential.
Any published document resulting from this study will not disclose your identity without
your permission. Information identifying you will only be available to the study personnel.
All data will be secured in a locked cabinet in a locked office.
WILL THERE BE ANY BENEFIT TO ME OR OTHERS?
Although you may not personally benefit from this study, your participation may help
clinicians and teachers when working with children with a diagnosis of Autism Spectrum
Disorder. Results of the study can provide insights to practitioners and teachers while
working with children with Autism Spectrum Disorder.
WHAT ARE MY RIGHTS AS A SUBJECT?
Your participation in this study is entirely voluntary. You may refuse to participate or
withdraw once the study has started. Your decision whether or not to participate or
terminate at any time will not affect your future standing with the researchers, the schools,
or the Inland Empire Autism Assessment Center of Excellence. You do not give up any
legal rights by participating in this study.
If, at any time, you feel uncomfortable with the questions on the surveys, you may refuse
to answer questions.
WHAT COSTS ARE INVOLVED?
There is no cost to you for participating in this study.
WILL I BE PAID TO PARTICIPATE IN THIS STUDY?
No.
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WHO DO I CALL IF I HAVE QUESTIONS?
You may call 909-558-4647 or e-mail patientrelations@llu.edu for information and
assistance with complaints or concerns about your rights in this study.
SUBJECT’S STATEMENT OF CONSENT
 I have read the contents of the consent form and have listened to the verbal
explanation given by the investigator.
 My questions concerning this study have been answered to my satisfaction.
 Signing this consent document does not waive my rights nor does it release the
investigators, institution or sponsors from their responsibilities.
 I may call Dr. Lee Berk during routine office hours at (909) 651-5828 (ext: 15828) if
I have additional questions.
 I hereby give voluntary consent to participate in this study.
I understand I will be given a copy of this consent form after signing it.

Signature of Subject

Printed Name of Subject

Date

INVESTIGATOR’S STATEMENT
I have reviewed the contents of this consent form with the person signing above. I have
explained potential risks and benefits of the study.

Signature of Investigator

Printed Name of Investigator

Date
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APPENDIX C
AUTHORIZATION FOR USE OF PROTECTED HEALTH INFORMATION

INSTITUTIONAL REVIEW BOARD
Authorization for Use of
Protected Health Information (PHI)
Per 45 CFR §164.508(b)
RESEARCH PROTECTION PROGRAMS
LOMA LINDA UNIVERSITY | Office of the Vice President of Research Affairs
24887 Taylor Street, Suite 202 Loma Linda, CA 92350
(909) 558-4531 (voice) / (909) 558-0131 (fax)/e-mail: irb@llu.edu

TITLE OF STUDY:
PRINCIPAL INVESTIGATOR:
Others who will use, collect, or
share PHI:

The Effect of High Antioxidant Cacao on Behaviors in Children
with Autism Spectrum Disorder
Lee Berk, DrPH
All Authorized Personnel

Use of the terms “I,” “you” and “your” addresses, where appropriate, the
study patient, the parent or legal representative if the study patient is a
minor, any unborn fetus(es) and child(ren) once born. The study named
above may be performed only by using personal information relating to your
health. National and international data protection regulations give you the
right to control the use of your medical information. Therefore, by signing
this form, you specifically authorize your medical information to be used or
shared as described below.
The following personal information, considered “Protected Health
Information” (PHI) is needed to conduct this study and may include, but is
not limited to: name, address, telephone number, date of birth, medical
records and charts, height, weight, school of attendance, current therapy
services the child receives such as but not limited to occupational therapy,
physical therapy, and speech therapy. Medical history of food allergies,
caffeine hypersensitivity, theobromine hypersensitivity, seizures or epilepsy,
developmental age < 24 months, and diabetes will also be obtained.
The individual(s) listed above will use or share this PHI in the course of this
study with the Institutional Review Board (IRB) of Loma Linda University,
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the sponsor of the study School of Allied Health Professions and its
affiliates, government agencies such as the Food and Drug Administration
(FDA), other research sites involved in this study, health care providers who
provide services to you in connection with this study, central labs, central
review centers and central reviewers.
The main reason for sharing this information is to be able to conduct the
study as described earlier in the consent form. In addition, it is shared to
ensure that the study meets legal, institutional, and accreditation standards.
Information may also be shared to report adverse events or situations that
may help prevent placing other individuals at risk.
All reasonable efforts will be used to protect the confidentiality of your PHI,
which may be shared with others to support this study, to carry out their
responsibilities, to conduct public health reporting and to comply with the
law as applicable. Those who receive the PHI may share with others if they
are required by law, and they may share it with others who may not be
required to follow national and international “protected health information”
(PHI) regulations such as the federal privacy rule.
Subject to any legal limitations, you have the right to access any protected
health information created during this study. You may request this
information from the Principal Investigator named above but it will only
become available after the study analyses are complete.
 The authorization expires upon the conclusion of this research study.
You may change your mind about this authorization at any time. If this
happens, you must withdraw your permission in writing. Beginning on the
date you withdraw your permission, no new personal health information will
be used for this study. However, study personnel may continue to use the
health information that was provided before you withdrew your permission.
If you sign this form and enter the study, but later change your mind and
withdraw your permission, you will be removed from the study at that time.
To withdraw your permission, please contact the Principal Investigator, Dr.
Lee Berk, or study personnel at 909-651-5828 (ext 15828).
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You may refuse to sign this authorization. Refusing to sign will not affect the
present or future care you receive at this institution and will not cause any
penalty or loss of benefits to which you are entitled. However, if you do not
sign this authorization form, you will not be able to take part in the study for
which you are being considered. You will receive a copy of this signed and
dated authorization prior to your participation in this study.
I agree that my personal health information may be used for the study
purposes described in this form.
Signature of Patient or Patient’s Legal
Representative

Date

Printed Name of Legal Representative (if any)

Representative’s Authority to Act for
Patient

Signature of Investigator Obtaining
Authorization

Date
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APPENDIX D
CALIFORNIA EXPERIMENTAL SUBJECT’S BILL OF RIGHTS

You have been asked to participate as a subject in an experimental clinical procedure.
Before you decide whether you want to participate in the experimental procedure, you have
a right to:
1. Be informed of the nature and purpose of the experiment.
2. Be given an explanation of the procedures to be followed in the medical experiment,
and any drug or device to be utilized.
3. Be given a description of any attendant discomforts and risks reasonably to be expected
from the experiment.
4. Be given an explanation of any benefits to the subject reasonably to be expected from
the experiment, if applicable.
5. Be given a disclosure of any appropriate alternative procedures, drugs or devices that
might be advantageous to the subject, and their relative risks and benefits.
6. Be informed of the avenues of medical treatment, if any available to the subject after
the experiment if complications should arise.
7. Be given an opportunity to ask any questions concerning the experiment or the
procedure involved.
8. Be instructed that consent to participate in the medical experiment may be withdrawn
at any time and the subject may discontinue participation in the medical experiment
without prejudice.
9. Be given a copy of any signed and dated written consent form used in relation to the
experiment.
10. Be given the opportunity to decide to consent or not to consent to a medical experiment
without the intervention of any element of force, fraud, deceit, duress, coercion or
undue influence on the subject's decision.
I have carefully read the information contained above in the “California Experimental
Subject’s Bill of Rights” and I understand fully my rights as a potential subject in a medical
experiment involving people as subjects.
________________________
Date

_________________________________
Patient
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APPENDIX E
PARTICIPANT’S DEMOGRAPHIC FORM
1. Name of Child _____________________________
2. Name of Parent (Informant) ___________________
3. Date of Birth _______________________________
4. Current Grade ______________________________
5. Gender:
 Male
 Female
6. How was your child diagnosed with Autism Spectrum Disorder?
 Pediatrician
 Neurologist
 School Psychologist
 Inland Empire Autism Assessment Center of Excellence
 Other (please specify):___________________________
7. Ethnicity: (Please check only one answer)
 White
 Hispanic or Latino
 Black or African American
 Native American or American Indian
 Asian
 Native Hawaiian or Other Pacific Islander
 Other (please specify): _____________________________
8. Current Employment: (Please check only one answer)
 Full-time
 Part-time
 Self-employed
 Out of work and looking for work
 Out of work but not currently looking for work (unemployed)
 Homemaker
 Military
 Retired
 Unable to work
 Other (please specify): ______________________________
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9. Highest Level of Education: (Please check only one answer)
 No schooling completed
 Primary school to 8th grade
 Some high school, no diploma
 High school graduate, diploma or the equivalent (GED)
 Some college credit, no degree
 Trade/technical/vocational training
 Associate Degree
 Bachelor’s Degree
 Master’s Degree
 Doctorate Degree
10. What is your current marital status? (Please check only one answer)
 Single
 Married
 Divorced
 Separated
 Widowed
11. If divorced, who has custody of the child?
 Mother
 Father
 Shared
 Other (please specify): ___________________________
12. What is your annual household income? (Please check only one answer)
 Less than $20,000
 $20,000 - $34,999
 $35,000 - $49,999
 $50,000 - $74,999
 $75,000 - $99,999
 $100,000 - $149,999
 $150,000 or more
13. Have any of the following stress events occurred in your life? (Check all that
apply)
 Parents divorced or separated
 Family illness
 Death in the family
 Parent changed job
 Change schools
 Family moved
 Family financial problems
 Other (please specify): _________________________
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14. Child’s Medical History: (Check all that apply)
 Seizures or Epilepsy
 Diabetes
 Food allergies
 Headaches
 Migraine headaches
 Attention Deficit Hyperactivity Disorder (ADHD)
 Anxiety or Depression
 Autism Spectrum Disorder
 Eating Disorder
 Sleeping Disorder
 Other: (please specify): _________________________
15. Average hours per night your child sleeps on weekdays: (Please check only one
answer)
 0-3 hours
 4-6 hours
 7-8 hours
 9 hours or more
16. Average hours per night your child sleeps on weekends: (Please check only one
answer)
 0-3 hours
 4-6 hours
 7-8 hours
 9 hours or more
17. Has your child ever had any of the following forms of treatment? (Check all that
apply)
 Individual psychotherapy
 If so, for how long: ___________________________
 Group psychotherapy
 If so, for how long: ___________________________
 Family therapy with child
 If so, for how long: ___________________________
 Speech therapy
 If so, for how long: ___________________________
 Occupational therapy
 If so, for how long: ___________________________
 Applied Behavioral Analysis (ABA)
 If so, for how long: ___________________________
 Physical therapy
 If so, for how long: ___________________________
 Early Intervention (Inland Regional Center, Early Head Start)
 If so, for how long: ___________________________
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18. Does your child have an Individualized Education Program?
 No
 Yes
19. What classroom setting is your child currently in?
 Special education: SDC mild/moderate
 Special education: SDC moderate/severe
 Special education: SDC severe/profound
 Mostly special education with some mainstreaming
 General education with RSP support
 General education (full inclusion)
 Has a “one on one” aid in special education or general education
 Other (please specify):_______________________
20. Where did you get a copy of the flyer to participate? (Check all that apply)
 Inland Empire Autism Assessment Center of Excellence
 WonderLAB
 Loma Linda University Outpatient Pediatric Rehabilitation Center
 Loma Linda University Interdisciplinary Outreach Clinic
 Drayson Center (Loma Linda)
 SenseAbilities
 Precious Hearts Academy
 High Desert Speech and Language Center Inc.
 Inland Regional Center
 Pediatric Therapy Associates (Chino)
 Anaheim Hills Pediatric Therapy Inc.
 Five Oaks Speech Clinic
 Horizon Therapy Services
 Nichols Speech Therapy
 Up & Movin Pediatric Therapy
 Redlands Community Hospital
 Autism Society Inland Empire (Facebook or newsletter)
 Clinical Trials Website
 Facebook
 Email
 Other (please specify): _____________________________
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APPENDIX F
ABERRANT BEHAVIOR CHECKLIST 2ND EDITION QUESTIONNAIRE
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APPENDIX G
AUTISM SPECTRUM RATING SCALE

100

101

APPENDIX H
PARENTAL STRESS INDEX SHORT FORM
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APPENDIX I
YOUTH AND ADOLESCENT FOOD FREQUENCY QUESTIONNAIRE
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APPENDIX J
DATA COLLECTION FORM
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APPENDIX K
LETTER OF RECRUITMENT FOR FLYER DISTRIBUTION
Date:
Letter of Agreement to Conduct Research

To Whom It May Concern,
I, ______________________________________, ____________________________, of
(name)
(title)
_____________________________________, agree to participate in a research study by
(organization/institution)
allowing the research recruitment to take place at (Name of site) per research projects’
protocol. This doctoral graduate student who is a licensed Occupational Therapist is
conducting a research study through Loma Linda University, School of Allied Health
Professions. The study is entitled “The Effect of High Antioxidant Cacao on Behaviors in
Children with Autism Spectrum Disorder.”

____________________________________
Signature

_____________________________________
Institution
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______________________
Date

APPENDIX L
ALLERGIC REACTION FACT SHEET

Potential allergic reactions to eating chocolate*:
“Chocolate may cause acne, allergic skin reactions, bloating, colic in infants,
constipation, decreased bone density, dental caries, eczema, gas, headaches, improved
insulin sensitivity, increased cholesterol levels, increased insulin levels, irregular heart
rhythms, increased oxalate levels in urine, irritable bowel syndrome, irritability,
jitteriness, kidney damage and disorders, migraines, nausea, neck pain, nervousness,
shakiness, sleep disturbances, stomach rumbling, stomach upset, swelling under the skin,
unpleasant taste, upset stomach, vomiting, weight gain.”
In the event that your child/student experiences any of these side effects:
1. Stop chocolate consumption immediately.
2. Consult with the school nurse if allergic reaction happens at school.
3. Consult your child’s health care provider immediately if they experience side
effects at home.
4. Call 911.
5. Report incident to Dr. Lee Berk at (909) 651-5828 (ext: 15828) and Amy Sadek at
951-212-2104.

Reference
*Mayo Clinic. (2013, November 1). Drug and Supplements: Chocolate. Retrieved from
http://www.mayoclinic.org/drugs-supplements/chocolate/safety/hrb-20058898
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APPENDIX M
FLYER FOR RECRUITING PARTICIPANTS
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